

University of Dundee

## Simplification of Care for Chronic Hepatitis C Virus Infection

Pawlotsky, Jean-Michel; Ramers, Christian B.; Dillon, John F.; Feld, Jordan J.; Lazarus, Jeffrey V.

*Published in:*  
Seminars in Liver Disease

*DOI:*  
[10.1055/s-0040-1713657](https://doi.org/10.1055/s-0040-1713657)

*Publication date:*  
2020

*Document Version*  
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

*Citation for published version (APA):*  
Pawlotsky, J.-M., Ramers, C. B., Dillon, J. F., Feld, J. J., & Lazarus, J. V. (2020). Simplification of Care for Chronic Hepatitis C Virus Infection. *Seminars in Liver Disease*, 40(4), 392-402. <https://doi.org/10.1055/s-0040-1713657>

### General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

### Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

This is the Author Accepted Manuscript of the following article, Pawlotsky, J-M., Ramers, C. B., Dillon, J. F., Feld, J. J., & Lazarus, J. V. (2020). Simplification of Care for Chronic Hepatitis C Virus Infection. *Seminars in Liver Disease*. <https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0040-1713657> which has been published in final form at: DOI: 10.1055/s-0040-1713657

# Simplification of Care for Chronic Hepatitis C Virus Infection

Jean-Michel Pawlotsky<sup>1</sup>, Christian B. Ramers<sup>2</sup>, John F. Dillon<sup>3</sup>, Jordan J. Feld<sup>4</sup>, Jeffrey V. Lazarus<sup>5</sup>

<sup>1</sup>National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Henri Mondor Hospital, University of Paris-Est, and INSERM U955, 51 avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France; [jean-michel.pawlotsky@aphp.fr](mailto:jean-michel.pawlotsky@aphp.fr)

<sup>2</sup>Division of Infectious Diseases, Department of Medicine, UC San Diego School of Medicine, 9500 Gilman Dr. La Jolla, CA, 92093, CA, United States; [christianr@fhcsd.org](mailto:christianr@fhcsd.org)

<sup>3</sup>Ward 2, Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, UK, DD1 9SY; [j.dillon@nhs.net](mailto:j.dillon@nhs.net)

<sup>4</sup>Toronto Centre for Liver Disease, University Health Network, Sandra Rotman Centre for Global Health 200 Elizabeth Street, 9EB-240 Toronto, Canada, ON M5G 2C4; [jordan.feld@uhn.ca](mailto:jordan.feld@uhn.ca)

<sup>5</sup>Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Calle del Rossellón 132, ES-08036, Barcelona, Spain; [jeffrey.lazarus@isglobal.org](mailto:jeffrey.lazarus@isglobal.org)

## Correspondence to:

Professor Jean-Michel Pawlotsky  
National Reference Center for Viral Hepatitis B, C and D  
Department of Virology,  
Henri Mondor Hospital  
51 Avenue du Maréchal de Lattre de Tassigny,

25 94010 Créteil, France

26 Tel.: +33-1-4981-2827

27 Fax: +33-1-4981-4831

28 Email: [jean-michel.pawlotsky@aphp.fr](mailto:jean-michel.pawlotsky@aphp.fr)

29

30 **Running head: Chronic Hepatitis C Virus Care Simplification**

31 **Keywords: hepatitis C virus, care cascade, screening, diagnosis, treatment**

32 **Word Count: 5749/6000**

33

34

## Abstract

In 2016, the World Health Organization (WHO) set a target for eliminating viral hepatitis as a major public health threat by 2030. However, while today's highly effective and well-tolerated pangenotypic direct-acting antiviral (DAA) regimens have maximized simplification of HCV treatment, there remain a plethora of barriers to HCV screening, diagnosis and linkage to care. As of 2017, only 19% of the estimated 71 million individuals living with chronic hepatitis C virus (HCV) worldwide were diagnosed and in 2015–2016, only 21% of diagnosed individuals had accessed treatment. Simplification and decentralization of the HCV care cascade would bolster patient engagement and support the considerable scale-up needed to achieve WHO targets. Recent developments in HCV screening and diagnosis, together with reduced pre-treatment assessment and on-treatment monitoring requirements, can further streamline the care continuum, ensuring patients are linked to care quickly and earlier in the disease course, and minimize clinic visits.

## Main Concepts and Learning Points

Today's highly effective, well-tolerated, all-oral, direct-acting antiviral combinations for the treatment of chronic hepatitis C virus infection have made elimination of the virus theoretically achievable by the World Health Organization's target of 2030
---

Despite the availability of curative hepatitis C virus treatments, most persons infected with hepatitis C virus remain untreated
--

Recent developments in hepatitis C virus screening and diagnostic procedures, as well as reduced pre-treatment assessments and on-treatment monitoring requirements, can simplify the hepatitis c virus continuum of care
---

Simplification of the hepatitis c virus care cascade would facilitate patient engagement and support the current concerted effort towards hepatitis c virus elimination
---

The journey from hepatitis c virus screening to cure can be achieved in as few as five steps and in as little as 20 to 24 weeks
---

## Introduction

The availability of highly effective, well-tolerated, all-oral, direct-acting antiviral (DAA) combinations for the treatment of chronic hepatitis C virus (HCV) infection has made the elimination of HCV a theoretically achievable goal within the next decade.[1] In May 2016, the World Health Organization (WHO) adopted their “Global Health Sector Strategy on Viral Hepatitis, 2016–2021,” which aims to eliminate viral hepatitis as a major public health threat by 2030 by reducing new chronic infections by 90% and mortality by 65%. To achieve this goal, 90% of individuals with chronic HCV infection need to be diagnosed, and 80% of those need to be treated.[2] Worldwide, however, the majority of people infected with HCV are not diagnosed and, therefore, remain untreated. In 2017, an estimated 71 million individuals were living with chronic HCV worldwide.[3] Of these, it is thought that only 13.1 million (19%) knew of their infection and only 5 million of those (38%) had accessed treatment by the end of 2017.[3] Simplification of the HCV care cascade, ideally at all steps in the continuum of care, would help to ensure that more patients remain engaged in the care pathway and ultimately support the considerable scale-up needed to achieve WHO targets.[4] In this article, we review the existing care pathway and discuss potential opportunities in which the patient journey from HCV screening to cure could be streamlined.

## Overview of the current HCV care pathway

Depending on the setting, and despite a current concerted effort towards simplification, the current HCV care pathway can be visualized as a sequence of anywhere up to 10 steps (**Fig. 1A**), from screening to cure, as advocated by international guidelines for HCV management, such as those from the American Association for the Study of Liver

Diseases (AASLD)/Infectious Diseases Society of America (IDSA),[5] the European Association for the Study of the Liver (EASL),[6] and WHO.[7] The steps can be grouped into three distinct phases: screening and diagnosis, pre-treatment, and treatment and monitoring (including post-treatment follow-up).

### *Screening and Diagnosis*

The screening and diagnosis phase includes screening for the presence of anti-HCV antibodies and confirming active HCV replication. Traditionally, screening of individuals at risk of HCV infection using an anti-HCV antibody test has been widely recommended, with periodic retesting for those at ongoing risk of (re)infection, such as people who inject drugs (PWID).[5-7] However, recent guideline updates have seen the broadening of this recommendation to one-time, routine, opt-out HCV testing for all individuals aged 18 years and older, with some also recommending testing in the prenatal setting during each pregnancy.[3,5,8,9] Other screening strategies include birth cohort testing or screening the general population in areas where HCV seroprevalence is intermediate ( $\geq 2\%$ ) or high ( $\geq 5\%$ ).[6,7] In individuals who are anti-HCV antibody positive, HCV replication is confirmed using a qualitative/quantitative HCV RNA test.[5-7] HCV core antigen detection and quantification may also be used to diagnose acute or chronic HCV infection.[6,7] With both assays, only the presence, not the amount, of marker is used for medical decisions. For payer reimbursement in some regions, namely the United States and Canada, two separate HCV RNA tests at least 6 months apart are required to confirm a diagnosis of chronic HCV infection. Guidelines now recommend that individuals with acute HCV infection are linked to appropriate care with a healthcare provider who will administer comprehensive management, rather than waiting for progression to chronic disease.[5,10]

100

101 *Pre-Treatment Phase*

102           For many patients, the pre-treatment phase includes an initial visit to a specialist  
103 (hepatologist, gastroenterologist, or infectious disease specialist) for pre-treatment  
104 assessments and selection of an appropriate HCV treatment. Prior to treatment initiation, a  
105 series of recommended tests are performed to identify viral and host factors that may  
106 impact the choice of treatment, prognosis, and/or required follow-up. In the DAA era, and  
107 with pangenotypic options available, the number of pre-treatment tests has been reduced;  
108 in particular, viral factors (eg, HCV genotype/subtype, presence of HCV drug resistance–  
109 associated substitutions) that may have previously impacted viral response and, therefore,  
110 treatment choice are not always required. However, it is still generally important to assess  
111 other active infections, such as hepatitis B virus (HBV) or human immunodeficiency virus  
112 (HIV), and confirm HCV genotype where appropriate.[5-7] Furthermore, it is considered  
113 good clinical practice to assess the degree of liver fibrosis in order to inform treatment  
114 decisions.[5-7]

115

116 *Treatment and Monitoring Phase*

117           In most cases, the choice of DAA and treatment duration have been based on HCV  
118 genotype, liver disease severity, and prior HCV treatment status. AASLD/IDSA guidance and  
119 2018 EASL recommendations advocate ribavirin-free DAA regimens, preferably  
120 pangenotypic if available (ie, those effective against the main HCV genotypes 1–6), for HCV  
121 treatment-naïve or -experienced adults without cirrhosis or with compensated cirrhosis.[3]  
122 Ribavirin is required in patients with decompensated cirrhosis.[5,6] In addition, EASL  
123 guidelines recommend combination regimens comprising two rather than three DAAs to



minimize the risk of adverse effects or drug–drug interactions.[6] Finally, WHO guidelines only recommend pangenotypic DAA regimens for all adults with or without cirrhosis.[7]

Although DAAs are generally well-tolerated, patients should be assessed for adverse events or potential drug–drug interactions at each visit or, according to WHO guidelines, at the end of treatment.[5-7] HBV reactivation during or after DAA treatment has been reported in patients who are hepatitis B surface antigen–positive and not receiving HBV antiviral therapy.[5] Therefore, patients meeting criteria for active HBV infection should be started on HBV antiviral therapy. Patients with low or undetectable HBV DNA levels can either receive prophylactic HBV therapy or be monitored for HBV reactivation during and immediately after HCV DAA therapy; HBV therapy should be initiated in patients with evidence of HBV reactivation.[5-7]

The final monitoring step is assessment of HCV cure, defined as a sustained virologic response (SVR; ie, undetectable HCV RNA) 12 weeks after completion of treatment (SVR12).[5-7] Some guidelines suggest SVR at 24 weeks after completion of treatment (SVR24) can also be used to define cure[6,7]; however, because of the high rate of concordance between SVR12 and SVR24 (sensitivity and specificity of 99% and 98%, respectively), the US Food and Drug Administration, and AASLD/IDSA guidelines, have defined HCV cure as SVR12.[5,11] Some patients may require additional monitoring, for instance to minimize drug–drug interactions between HCV DAAs and anti-HIV medications or immunosuppressants that could jeopardize graft success in liver transplant recipients.[5,6] Patients with advanced cirrhosis should also be monitored closely during treatment, and for hepatocellular carcinoma (HCC) after treatment.[5-7]

## **Simplifying the HCV Care Pathway**

The current HCV care pathway is complex and often difficult to navigate for many patients, with multiple office visits, blood draws, assessments, and interactions with different healthcare providers and payers. This level of continuous care can be a particularly challenging barrier in some populations that require specific public health approaches because of a high incidence of HCV, high prevalence of HCV, stigma, discrimination, criminalization or vulnerability, and/or difficulty accessing healthcare services, such that they would benefit from a streamlined care pathway.[7] Examples of such populations include PWID, prisoners, homeless individuals, migrants, those in rural communities with poor access to care, those struggling with mental health or substance use disorders, some groups of men who have sex with men, sex workers, and indigenous populations who are historically less engaged in healthcare. In addition, the current pathway requires high-level laboratory and clinical capabilities to diagnose infection, identify the HCV genotype, assess fibrosis, and monitor treatment. These requirements potentially create barriers for HCV care management.

Based on recent advances in diagnostic techniques and HCV treatments, the current HCV care pathway can be streamlined (**Fig. 1B**), and simplification of care is an increasing focus within the field of HCV treatment.[4] Simplification will potentially have multiple benefits, including better allocation of resources to diagnose and treat more patients (expanding access and coverage), acceleration of treatment initiation (linkage to care), reduction in HCV transmission among high-risk populations (treatment as prevention), improvement in patient adherence, facilitation of task-sharing/patient management by non-specialists, and lowering the long-term medical costs of untreated HCV infection, such as those associated with advanced liver disease, extra-hepatic complications of HCV infection, or liver transplant.

For many patients, the ideal HCV care pathway would involve diagnosis, pre-treatment work up, and treatment initiation in a single day. A US study modeled the impact of a hypothetical “consolidated” HCV care pathway that required at least two visits for patients to receive treatment.[12] In this scenario, a positive anti-HCV test led immediately to an HCV RNA test, HCV genotyping, and fibrosis staging, which took place during a single visit. Referral to a specialist was required only for patients with moderate to advanced fibrosis (METAVIR stage  $\geq$ F2); therefore, an estimated 40% of patients could be managed by their primary care provider. Compared with the current HCV care pathway that requires at least four visits before receiving treatment, the consolidated pathway reduced the percentage of patients lost to follow-up from screening to treatment from 71–76% (depending upon the insurance provider) to 4–5%. Therefore, reducing the steps in the care pathway increased the number of patients who learned of their HCV status, were linked to care, and received HCV treatment. The cost to identify and link to care one additional patient with HCV was \$1586–\$2546 with the current HCV care pathway and \$212–\$548 with the consolidated pathway.[12] However, these findings may not be generalizable to all geographical settings or certain high-risk populations.

### **Simplifying the Screening and Diagnosis Phase**

Screening and diagnostic services need to reach much larger numbers of individuals with HCV infection to achieve the WHO elimination target of 90% diagnosed by 2030. Strategies to increase anti-HCV screening and diagnosis rates include risk factor–based screening, universal screening in specific populations, simplification of sampling using capillary whole blood, dried blood spot (DBS) testing, and point-of-care (PoC) testing using rapid diagnostic tests (RDTs).

## *Screening Programs*

Risk factor–based anti-HCV screening has previously been a prominent feature of international guidelines. However, screening for specific risk factors for HCV infection (ie, risk behaviors or exposures) has largely been unsuccessful because of patients’ reluctance to disclose these risks and provider limitations in collecting risk information.[5] Population-based screening methods may be more successful (ie, identifying and screening populations that have a relatively high prevalence of HCV infection). For example, in the United States, 50% of all HCV infections occur in individuals born between 1945 and 1965; therefore, one-time HCV testing has been recommended in this birth cohort.[13] Nevertheless, screening rates are still low in this population because of, among other reasons, the stigma associated with HCV infection, the asymptomatic course of the disease, the lack of awareness of testing recommendations, and low healthcare engagement of the most at-risk populations.[14]

However, recent guideline updates have seen recommendations for screening broaden to include routine one-time HCV testing for all individuals aged 18 years and older.[3,5,8,9] Practical implementation measures, such as electronic medical record prompts, that have been shown to significantly increase screening rates in individuals born between 1945 and 1965 may help to facilitate universal screening and alleviate any stigma related to the disease. For example, in one study of this demographic group, screening rates increased from 7.6% during the 6 months before their introduction to 72% over the year after their introduction.[15]

PWID have been identified as a priority population for HCV elimination. Worldwide, approximately 40% of people with recent injecting drug use are infected with HCV and 9% of all people living with HCV infection are those who recently injected drugs, with wide

variation among countries.[16] It has been estimated that 43% of all new HCV infections could be prevented over 12 years (2018–2030) if the HCV transmission risk associated with PWID was removed over that period.[17] Uptake of HCV treatment in this group is historically low,[18] despite guideline recommendations to regularly screen PWID for HCV.[5-7] The challenge for screening this population is the lack of engagement with traditional sources of healthcare; therefore, alternative options must be explored. One successful strategy is to integrate HCV screening programs into harm reduction and community outreach facilities, thereby offering a comprehensive “one-stop strategy” at the PoC for HCV screening and diagnosis, treatment initiation, and follow-up. Such approaches have been successfully implemented in several countries including France,[19] Switzerland,[20] and the United States.[21] In Scotland, the launch of the Hepatitis C Action Plan introduced DBS sampling into community drug services to increase access to testing.[22] Between the pre–Action Plan (1999–2006) and Action Plan (2007–2011) periods, the average number of annual tests increased from 67 to 973; the percentage of individuals testing positive for HCV also increased across these periods (from 19% to 38%).

Unfortunately, screening birth cohorts and high-risk populations such as PWID will not find all of the remaining individuals infected with HCV. Achieving WHO elimination targets will require the adoption of broader, simpler screening policies. Different regional strategies will be needed because of the variable global epidemiology of HCV infection.[16] One strategy under consideration is universal anti-HCV screening of all adults. Egypt, which has the highest prevalence of HCV worldwide and access to low-cost generic DAA treatments, has embarked on one such program: following a campaign of targeted screening, all adults aged 18 years and older are now being screened.[23] This approach may be too costly in regions with low HCV prevalence because of the large number of

patients needed to be screened. However, modeling studies in France and the United States have shown universal screening can be cost-effective in low prevalence regions.[24,25] Indeed, the US Preventative Services Task Force has recently updated their recommendations to include HCV screening for all adults 18–79 years of age.[8] Likewise, the US Centers for Disease Control & Prevention (CDC) recently updated their recommendations to include screening of all adults aged 18 years and older in addition to all pregnant women; except in settings where the prevalence of HCV is less than 0.1%.[9]

HCV screening in pregnancy represents an important opportunity for healthcare provider interaction with women of childbearing age, in whom rates of HCV have been increasing in recent years.[26] The prevalence of HCV antibodies in pregnant women is thought to be 0.1–3.6% worldwide, and some studies suggest that chronic HCV infection is associated with an increased risk for adverse neonatal outcomes.[27] Furthermore, vertical transmission of HCV from mother to child will occur in up to 5% of cases of HCV monoinfection and is a common source of HCV infection in children.[28]

Around 3.5 million children are estimated to be infected globally,[28] representing an important pool of unidentified HCV cases, with as many as 95% of HCV-infected children in the United States of America remaining undiagnosed.[29] In one study including 119 perinatally infected patients, 38% of those aged >33 years had developed cirrhosis, despite the low prevalence of traditional risk factors.[30]

Alternatively, pragmatic approaches to screening strategies, such as random selection or using a hub-and-spoke model as trialed in Italy, can provide a practical compromise between universal and targeted screening.[31]

Regardless of the model employed and populations targeted, screening to identify undiagnosed cases is vital in achieving elimination targets.

## *Virologic Tools to Simplify HCV Screening*

PoC testing provided outside traditional centralized laboratories can be used with the goal of delivering test results to patients during the same visit.[32] PoC testing relies extensively on the use of one of the many RDTs available for anti-HCV antibody detection, several of which are prequalified by WHO.[33] RDTs can be performed in 20 minutes for anti-HCV antibodies using whole blood obtained by venipuncture or finger prick, or oral fluid. Anti-HCV antibody RDTs have excellent sensitivity and specificity compared with ELISA-based laboratory methods (98% and 100%, respectively).[34] RDTs are valuable in high-throughput settings where results are needed quickly, such as prisons and harm reduction programs. An example of the value of RDTs within a harm reduction setting is provided by Bregenzer et al., where the introduction of an anti-HCV antibody RDT led to 23.9% of PWID undergoing HCV screening, compared with only 2% prior to its introduction.[35]

Confirmation of infection after detection of anti-HCV antibodies requires HCV RNA or core antigen testing. A few PoC HCV RNA assays, which generate results from plasma or whole blood within 60 to 90 minutes, are available.[32] The increasing availability of such assays in high-income settings has the potential to transform HCV testing. In low-income countries, providers need to take advantage of the availability of such technologies, which to date have typically been used for HIV or tuberculosis testing.

To meet the WHO goal of identifying 90% of all HCV-infected individuals, PoC testing needs to be implemented into non-traditional settings to capture individuals not actively engaged in healthcare, including emergency departments, obstetric centers, surgical and psychiatric wards, dental clinics, and pharmacies.[36-41] Potential benefits of increased PoC

testing include reducing the number of clinic visits, which may increase screening and treatment rates, and reducing late presentation, which is common in patients with HCV.[42]

Using DBS samples is an alternative method to PoC testing. A few drops of fingerstick whole blood are placed onto a special absorbent filter paper. After desiccation, DBS can be shipped as non-hazardous materials using regular mail or courier services to reference laboratories for anti-HCV antibody and HCV RNA assessments.[32] DBS diagnostic accuracy is high for anti-HCV antibodies (sensitivity, 96.1%; specificity, 99.2%) and HCV RNA (sensitivity, 97.8%; specificity, 99.2%), with no relevant differences in diagnostic accuracy according to the type of test used.[43] DBS has distinct advantages over blood and oral fluid in terms of ease of transport and storage and may be particularly useful in low- and middle-income countries with high HCV prevalence and limited healthcare infrastructure. In high-income countries, DBS could be used where facilities and treatment for PWID or migrant populations are community located and staffed by workers with limited clinical training.

#### *Methods to Improve Linkage to Care*

In addition to increasing screening rates, loss to follow-up between screening and diagnosis must be reduced. Studies in Europe and the United States show that 69% and 47% of screened patients, respectively, did not receive a confirmatory diagnosis of HCV infection.[44,45] Some countries have higher diagnosis rates, particularly those with national screening plans, such as France (74%) and Australia (75%).[46,47] Reinforcing the link between screening and diagnosis will ensure better identification of infected individuals and improve rates of retention in the HCV care pathway. The screening and diagnosis phase will continue to be a two-step process until it becomes more cost-effective to perform a single HCV RNA test to confirm active HCV infection (eg, in areas with very high HCV



prevalence). Alternatively, advances such as reflex testing combine these steps into a single clinic visit.

Reflex HCV RNA testing, in which a positive anti-HCV test triggers an immediate HCV RNA test on the same sample, eliminates an extra visit for a new sample and enables more rapid linkage to care.[12] Reflex HCV RNA testing, as used by the US Veterans Affairs (VA) system,[48] is important in large health systems, with centralized testing where most patients are actively engaged in care and undergoing phlebotomy rather than PoC testing.[48] However, this approach may be suitable for some field-based PoC approaches outlined above. AASLD/IDSA guidelines recommend that harm reduction programs offer anti-HCV testing with reflex or immediate confirmatory HCV RNA testing,[5] 2018 EASL recommendations state that reflex HCV RNA testing should be applied whenever possible,[6] and WHO guidelines include reflex HCV RNA testing as an approach to promote linkage to care in all patients with HCV.[7]

Increases in screening and diagnosis rates will have a limited impact on WHO elimination targets without concomitant improvements in linkage to care. Although specialist referral may be required for some complex cases, most patients could be treated by their primary care provider if the providers were given adequate training.[7] Therefore, the role of the primary care provider is considered critical for expanding access to HCV care, especially in areas of high HCV prevalence.[49] Recently released “Simplified HCV Treatment Algorithms” from AASLD/IDSA reinforce the concept that less complex cases can be successfully managed by primary care providers with less intensive monitoring.[50,51] Indeed, decentralizing HCV treatment to utilize primary care physicians significantly increased treatment uptake in PWID in Australia and New Zealand compared with hospital-based specialist care (75% vs 34%), with significantly higher cure rates (49% vs 30%).[52]

Telementoring programs can be used to educate and support non-specialist providers. These programs take advantage of approaches such as videoconferencing and knowledge networks to establish close collaborations between HCV specialists and primary care providers or other healthcare professionals. One such program, the VA-Extension for Community Healthcare Outcomes (ECHO) program, demonstrated an increase in the rate of primary care provider–initiated HCV treatment from 2.5% to 21.4% ( $p < 0.01$ ) with program participation.[53] The ECHO model also demonstrated that HCV treatment administered by non-specialist providers was as safe and effective as that provided by specialists in underserved populations.[54] An alternative telementoring approach investigated in the ASCEND study indicates that under specialist oversight, nurse practitioners or primary care physicians only required a short 3-hour training session to treat patients as effectively as specialists.[55] Decentralizing HCV care from specialists to primary care providers, as well as other healthcare professionals such as addiction specialists, prison doctors, and advanced practice providers, would simplify the continuum of care and expand access to HCV treatments without compromising outcomes.[56] Furthermore, integrating HCV care pathways with those for common copathologies such as HIV, malaria or sexually transmitted diseases represents another important method for expanding access to HCV diagnosis and treatment[57-59] and can increase HCV diagnosis and treatment uptake.[59,60]

## **Simplifying the Pre-Treatment Phase**

### *Assessing Liver Fibrosis*

Once chronic HCV infection has been confirmed, patients undergo several pre-treatment assessments.[5-7] Staging of liver fibrosis by at least one method is required for all patients prior to treatment to determine the need for post-treatment monitoring (ie, bi-

annual HCC ultrasound screening) in patients with advanced fibrosis (METAVIR score F3) or cirrhosis (METAVIR score F4).[5-7] If advanced fibrosis or cirrhosis is present, these patients should be referred to a specialist provider for their continued care requirements. However, the remaining population with HCV infection is evolving to generally be younger and have milder liver disease,[61,62] which may help to support more non-specialist provider involvement.

Although biopsy was previously used for assessing liver fibrosis, the procedure is invasive and minor complications are common. Alternative, validated and non-invasive methods including serologic, physical, and imaging protocols have replaced biopsy and are preferred to stage liver fibrosis.[63] Simplifying the initial liver fibrosis assessment using non-invasive methods would enable decision-making by non-specialist providers, which would reduce referrals to specialists and improve access to care for patients. This could be particularly impactful for high-risk groups, such as PWID, who may already be managed in a number of health care settings.[64,65]

The calculation of an aspartate aminotransferase (AST)-to-platelet ratio index (APRI) score using AST concentrations and platelet count has excellent negative predictive value and can identify patients not at risk for advanced liver fibrosis who could be easily managed by non-specialist providers.[63] In a prospective study in treatment-naïve patients chronically infected with HCV genotype 1–6 and no history of cirrhosis, APRI  $\leq 1$  was used to select patients for 8 weeks' treatment with the pangenotypic DAA combination glecaprevir/pibrentasvir.[66] The results showed that APRI  $\leq 1$  (mean, 0.41; range, 0.13–1.00) identified patients without cirrhosis who could then be appropriately treated by non-specialist providers. Fibrosis-4 (FIB-4) is another tool that uses a formula based on age, AST, platelets, and alanine aminotransferase to score fibrosis.[63] FibroTest is a laboratory-

387 ordered test using a proprietary formula based on age, gender, and five additional  
388 biomarkers.[63] Transient elastography (eg, FibroScan®) measures liver stiffness to assess  
389 fibrosis; in addition, other physical technologies have been developed to assess liver  
390 fibrosis.[63] FibroScan and FibroTest use may be restricted by cost and availability in  
391 resource-limited settings. AASLD/IDSA guidelines recommend liver biopsy and/or non-  
392 invasive markers to evaluate liver fibrosis in patients with chronic HCV infection.[5] The new  
393 simplified algorithms from AASLD/IDSA emphasize the utility of non-invasive tests for  
394 fibrosis assessment.[50,51] EASL and WHO guidelines recommend non-invasive methods,  
395 especially APRI and FIB-4, outside specialty clinics in resource-limited settings.[6,7]

396

#### 397 *HCV Genotype Determination*

398 With the introduction of pangenotypic DAAs, some guidelines consider that the need  
399 for HCV genotyping is reduced, particularly where tests are not available or not affordable,  
400 or to improve access by simplifying the care pathway.[5-7] However, identifying patients  
401 infected with genotype 3, particularly those who have cirrhosis, remains important because  
402 SVR rates can be impacted by prior HCV treatment experience or the presence of NS5A  
403 inhibitor resistance—associated substitutions at baseline.[5-7] Longer treatment durations,  
404 baseline resistance testing, or the addition of a third drug (eg, a DAA with another target or  
405 ribavirin) may be required in patients with HCV genotype 3 infection and cirrhosis. The  
406 decision to identify the HCV genotype may ultimately be one of cost-effectiveness (ie,  
407 relative cost of regimens without genotype 3 restrictions) and the epidemiologic profile of  
408 endemic HCV genotypes within specific regions. WHO guidelines stipulate that where HCV  
409 genotype 3 prevalence is <5%, genotyping could be excluded and a uniform pangenotypic  
410 treatment duration used.[7]

However, the prevalence of other potentially difficult-to-treat genotypes such as non-1a/b subtypes of GT1 or non-4a/d subtypes of GT4 are increasing worldwide, largely driven by migration from areas of high endemicity for these subtypes, such as sub-Saharan Africa (SSA).[67] These subtypes are associated with higher failure rates to earlier NS5A inhibitors than other subtypes, with sofosbuvir/velpatasvir/voxilaprevir the only currently approved re-treatment option for those failing initial NS5A-based regimens.[67] This potentially poses a barrier to re-treatment success, as there is limited routine access to this therapy in SSA. Furthermore, settings that cannot access this treatment rely on viral sequencing to inform decision making regarding the most suitable alternative treatment options, but this is also not routinely available in SSA. It will therefore be crucial for settings such as these to increase access to newer pangenotypic regimens, as well as testing and documenting patient genotypes and resistance profiles, in order to monitor the success of first- and second-line HCV treatments.[67]

## **Simplifying the Treatment and Monitoring Phase**

### *Treatment*

Despite the availability of curative HCV treatments, most persons infected with HCV remain untreated.[68] International guidelines recommend that all persons diagnosed with chronic HCV infection should be considered for treatment.[5-7] Adopting a “treat all” approach helps to simplify clinical decision-making; streamline patient management; reduce transmission, morbidity, and mortality; and, ultimately, furthers progress towards WHO elimination targets.

Access restrictions to HCV treatment remain a significant barrier to care in many countries.[69,70] Depending upon the country or healthcare system, access can be

restricted by one or more of the following: high cost, the degree of liver disease (eg, only patients with progressive liver disease [METAVIR stage  $\geq$ F2] can receive DAAs), the prescribing physician (eg, only specialists can prescribe DAAs), or recent illicit drug or alcohol abuse (eg, only patients enrolled in an addiction management program or with demonstrated sobriety can receive DAAs).[69,70] Most restrictions are not evidence-based or supported by guidelines. For example, guidelines state that recent or active injection drug use is not a contraindication to HCV therapy.[5-7] Numerous studies have demonstrated a lack of impact on treatment adherence and high cure rates with DAAs among recent or active drug users.[71,72] Although these restrictions are slowly being lifted in the United States, over 30 state Medicaid plans still have prescriber and sobriety restrictions in place, and ~15 states have fibrosis score restrictions; removing these will improve access to HCV treatment for all patients and is a key recommendation in the US National Strategy to eliminate viral hepatitis.[69,70,73]

The latest DAA combinations have transformed the treatment landscape for chronic HCV infection, offering high cure rates with favorable safety profiles.[7] The fixed-dose DAA combinations glecaprevir/pibrentasvir and sofosbuvir/velpatasvir are pangenotypic, well-tolerated, have virologic cure rates >95%, and treatment courses of 8–12 weeks for most patients.[6,7,74,75]

Improving access to HCV treatment worldwide is vital, and in low-to-middle income countries, generic formulations of approved HCV treatments represent an important step towards making HCV elimination an achievable goal.[68] Globally, over 60% of people with HCV infection live in countries with access to affordable generic DAAs,[68] such as generic formulations of sofosbuvir and daclatasvir, also considered pangenotypic, at costs as low as approximately US \$60 per 12-week supply.[76] Many of these countries have negotiated

discounts from manufacturers to help provide universal access to HCV treatment with minimal financial contributions required by patients.[77]

These generic formulations provide a viable option for HCV treatment, as a recent systematic review and meta-analysis of the effectiveness of generic formulations demonstrated equivalent outcomes between generic and licenced DAA formulations in the treatment of HCV.[78]

The treatment profiles of the pangenotypic DAAs support the practicality of a “treat all” approach and have already helped to streamline the HCV care pathway by simplifying treatment choice.[6,7] However there is further room for expansion to include indications for children under the age of 12 years, who represent an important population to target to achieve elimination efforts. Indeed, AASLD/IDSA guidelines state that the approval of additional DAA regimens for children aged 3–11 years is anticipated in the near future,[5] and sofosbuvir/velpatasvir has recently been approved for use in children from 6 years of age.[75]

#### *On-Treatment Monitoring*

There appears to be no requirement for on-treatment monitoring for virologic efficacy, given the very high cure rates with current DAA combinations, and steps towards simplification with regards to this aspect of HCV treatment have already been made. AASLD/IDSA guidelines previously recommended that HCV RNA viral load was assessed 4 weeks after treatment initiation, 12 weeks after therapy completion (SVR12), and as a consideration at the end of treatment.[5] However, evidence suggests HCV RNA measurements at 4 weeks and at the end of treatment are unnecessary because they are not predictive of SVR12. In a retrospective review of 208 patients infected with HCV

483 receiving DAAs, no difference was reported in SVR12 rates between patients with  
484 detectable and undetectable HCV RNA at week 4 (96.5% vs 97.5%;  $p=0.69$ ).[79] These  
485 results have been replicated irrespective of treatment regimen or duration.[80,81]  
486 AASLD/IDSA guidelines have recently been updated to dispense with 4-week HCV RNA viral  
487 load assessment, now recommending testing only at 12 or more weeks post-treatment  
488 completion.[5] Furthermore, 2018 EASL recommendations advocate HCV RNA viral load  
489 testing at 12 or 24 weeks post-treatment only but state SVR assessment is dispensable,  
490 given the high cure rates expected with pangenotypic regimens.[6] WHO recommends viral  
491 load testing at 12 or 24 weeks post-treatment.[7] Patients at risk for reinfection should be  
492 tested for SVR12 and yearly thereafter whenever possible.[6]

493         Another strategy aimed at reducing the reliance on clinic visits and simplifying on-  
494 treatment patient monitoring is telemedicine (or telecare). Telemonitoring or teleconsulting  
495 programs, which use telephone contact instead of clinic visits, can be used to ensure  
496 medication adherence and monitor for adverse events and potential drug–drug interactions.  
497 These programs have been successful in underserved populations, such as prisoners.[82]  
498 Simplified HCV treatment monitoring via telephone calls versus standard clinic visits was  
499 assessed in the SMART-C study, and no differences were seen in virologic or safety  
500 outcomes in “easy-to-manage” patients.[83] Taken together with the simplicity, safety, and  
501 effectiveness of the latest DAA regimens, measures aimed at reducing clinic visits, especially  
502 in high prevalence settings, will relieve the burden on healthcare systems.[84] These  
503 strategies will facilitate the retention of patients in care, supporting patients’ preferences  
504 for treatment attributes that offer more convenience and require less disruption to daily life  
505 (eg, shorter treatment duration and fewer office visits).[85]



In the past, concerns regarding low treatment adherence to interferon-based therapies in PWID meant that additional on-treatment monitoring was warranted.[64,86] However, in the DAA era, evidence suggests that treatment adherence and SVR rates are high in PWID. In the SIMPLIFY study, median adherence to sofosbuvir/velpatasvir for 12 weeks was 94% in PWID with recent injection drug use ( $\leq 6$  months), with 32% of patients considered non-adherent ( $< 90\%$  adherence).[71] Although adherence decreased during therapy, similarly high SVR12 rates were seen in PWID who were adherent ( $\geq 90\%$  of doses received) and non-adherent (94% vs 94%,  $p=0.944$ ).[71] In the ongoing ANCHOR study, in which 97 PWID with recent injection drug use ( $\leq 3$  months) received sofosbuvir/velpatasvir for 12 weeks, SVR12 was achieved by 90% of PWID who attended the week 24 visit.[72] SVR12 rates were unaffected by treatment interruptions that delayed the anticipated date for end of treatment, providing the treatment course was completed.[72] Additional monitoring for treatment adherence in PWID is no longer warranted; instead, pre-therapeutic education and on-treatment support delivered via a decentralized multidisciplinary care approach are important for successful treatment in PWID.

506

#### 507 **Status: Simplifying the HCV Care Pathway**

508         Simplifying the diagnosis, treatment, and monitoring of patients with chronic HCV  
509 infection has improved the prospects for scaling-up the management of patients by primary  
510 care providers and other non-specialist healthcare professionals to further progress towards  
511 achieving the WHO goal of HCV elimination.[87] AASLD/IDSA acknowledge that treatment  
512 simplification could expand the number of healthcare providers who can prescribe HCV  
513 therapy and increase the number of individuals who are treated.[5] EASL recommendations  
514 are also comprehensive but propose that simplified HCV care pathways are now possible

using a pangenotypic DAA regimen for 12 weeks.[6] Recent label updates mean that treatment-naïve patients without cirrhosis or with compensated cirrhosis can now both receive glecaprevir/pibrentasvir for 8 weeks. The only assessments required are to confirm chronic HCV infection and advanced fibrosis or cirrhosis (using non-invasive markers) and establish possible drug–drug interactions. Genotyping can be dispensed with, and SVR12 assessment is not required in, patients who are adherent and not at high risk for reinfection.[6] WHO also has specific recommendations to support their “treat all and use pangenotypic DAAs” recommendation, including simplified treatment pathways and decentralization of testing and treatment services at the primary care level.[7] Simpler HCV care pathways to encourage HCV testing and treatment at the primary care level have been successful in expanding treatment in France[88] and Australia,[89] for example.

## **Conclusions**

Today’s highly effective, safe, and well-tolerated pangenotypic DAA regimens have maximized the opportunity to simplify treatment strategies in the HCV care pathway. Recent developments in HCV screening and diagnostic procedures, together with lower requirements for pre-treatment assessments and on-treatment monitoring, can further streamline the continuum of care, ensuring more patients are linked to care quickly and earlier in the disease course, and with minimal clinic visits. These advances also allow HCV treatment to be prescribed by non-specialist providers, which can reduce overall healthcare costs and further support efforts towards meeting the WHO viral hepatitis elimination goal. Patients and healthcare providers should both be motivated to embark on a simplified HCV care pathway by knowing that, if diagnosed with chronic HCV, the journey from screening to cure can be achieved in as few as five steps and in as little as 20 to 24 weeks.

## Acknowledgements

Medical writing support was provided by Paul MacCallum, PhD, and Heather Shawcross, PhD, of Fishawack Communications, Ltd, and funded by AbbVie. AbbVie funded the publication and participated in the writing, reviewing, and approval of the publication. All authors have had access to relevant data and participated in the drafting, review, and approval of this publication. Eric Crown, PhD, Doug Dylla, PhD, and Dimitri Semizarov, PhD, all of AbbVie Inc, also reviewed and provided feedback on the manuscript.

## Disclosures

**Jean-Michel Pawlotsky:** research grants from Abbot and Vela Diagnostics; advisor for Abbvie, Gilead, GlaxoSmithKline, Merck, Regulus, and Siemens Healthcare; speaker for Abbvie and Gilead.

**Christian B. Ramers:** research grants from AbbVie, Gilead; consulting/speaking fees from AbbVie, Gilead, Merck, Viiv outside of the published work.

**John F. Dillon:** research grants and personal fees from AbbVie, Janssen, Roche, Gilead Sciences, and MSD; grants from CEPHEID, Genedrive, and GlaxoSmithKline, outside the submitted work.

**Jordan J. Feld:** research grants for Abbvie, Gilead, Janssen, and Wako/Fujifilm; consulting for Abbvie, Gilead, Enanta, Janssen, and Roche

**Jeffrey V. Lazarus:** research grants and personal fees from AbbVie, Gilead Sciences and MSD; personal fees from CEPHEID, GlaxoSmithKline, Intercept, and Janssen, outside the submitted work.

**Fig. 1. Overview of the HCV care cascade (A) the traditional care cascade, and (B) a potentially simplified HCV care cascade for treatment-naïve patients without cirrhosis managed in a primary care setting.**

\*Pre-treatment assessments previously recommended by AASLD/IDSA and EASL: HCV genotype and subtype; HCV viral load; fibrosis staging; HBV co-infection; HIV co-infection; complete blood count; international normalized ratio; hepatic function panel; estimated glomerular filtration rate; potential drug-drug interactions.

†On-treatment monitoring previously recommended by AASLD/IDSA: HCV viral load; creatinine level; estimated glomerular filtration rate; hepatic function panel.

‡On-treatment monitoring previously recommended by WHO: Routine laboratory monitoring for treatment toxicity.

§Post-SVR12 monitoring recommended by AASLD/IDSA and EASL: surveillance for hepatocellular carcinoma by twice-yearly ultrasound examination in patients with advanced fibrosis (ie, Metavir stage F3 or F4).

¶With reflex testing, screening and diagnosis can be combined to enable confirmatory HCV diagnosis with fewer patient visits. AASLD/IDSA, American Association for the Study of Liver Diseases/Infectious Diseases Society of America; EASL, European Association for the Study of the Liver; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; RNA, ribonucleic acid; SVR12, sustained virologic response 12 weeks after completion of treatment; WHO, World Health Organization

## References

1. Cooke GS, Andrieux-Meyer I, Applegate TL et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. *Lancet Gastroenterol Hepatol* 2019; 4: 135-184
2. World Health Organization (WHO). *Global health sector strategy on viral hepatitis, 2016–2021: Towards ending viral hepatitis*, <https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf;jsessionid=3353B8BE60FB5081680122276F404913?sequence=1> (2016) Accessed: April 2020.
3. World Health Organization (WHO). *Hepatitis C: key facts*, <https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-c> (2019) Accessed: April 2020.
4. Lazarus JV, Pericàs JM, Picchio C et al. We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. *Journal of Internal Medicine* 2019; 286: 503-525
5. American Association for the Study of Liver Diseases (AASLD) IDSoAI. *HCV guidance: Recommendations for testing, managing, and treating hepatitis C*, [www.hcvguidelines.org](http://www.hcvguidelines.org) (2019) Accessed: April 2020.
6. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. *J Hepatol* 2018; 69: 461-511
7. World Health Organization (WHO). *Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection*, <https://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2018/en/> (2018) Accessed: April 2020.
8. US Preventive Services Task Force. *Hepatitis C Virus Infection in Adolescents and Adults: Screening*,

<https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/hepatitis-c-screening1> (2020) Accessed: April 2020.

9. Centers for Disease Control. CDC Recommendations for Hepatitis C Screening Among Adults — United States, 2020. MMWR Morbidity and mortality weekly report 2020; 69: 1–18
10. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264
11. Mishra P, Murray J, Birnkrant D. Direct-acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: Scientific and regulatory approaches to clinical trial designs. Hepatology 2015; 62: 1298-1303
12. Mulligan K, Sullivan J, Yoon L et al. Evaluating HCV screening, linkage to care, and treatment across insurers. Am J Manag Care 2018; 24: e257-e264
13. Smith BD, Morgan RL, Beckett GA et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61: 1-32
14. Jemal A, Fedewa SA. Recent hepatitis C virus testing patterns among baby boomers. Am J Prev Med 2017; 53: e31-e33
15. Konerman MA, Thomson M, Gray K et al. Impact of an electronic health record alert in primary care on increasing hepatitis c screening and curative treatment for baby boomers. Hepatology 2017; 66: 1805-1813
16. Grebely J, Larney S, Peacock A et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction 2019; 114: 150-166
17. Trickey A, Fraser H, Lim AG et al. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol 2019; 4: 435-444

18. Iversen J, Grebely J, Topp L et al. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011. *J Viral Hepat* 2014; 21: 198-207
19. Delile JM, de Ledinghen V, Jauffret-Roustide M et al. Hepatitis C virus prevention and care for drug injectors: the French approach. *Hepatol Med Policy* 2018; 3: 7
20. Scherz N, Bruggmann P, Brunner N. Direct-acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatment. *Int J Drug Policy* 2018; 62: 74-77
21. Akiyama MJ, Norton BL, Arnsten JH et al. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial. *Ann Intern Med* 2019; 170: 594-603
22. McLeod A, Weir A, Aitken C et al. Rise in testing and diagnosis associated with Scotland's Action Plan on Hepatitis C and introduction of dried blood spot testing. *J Epidemiol Community Health* 2014; 68: 1182-1188
23. Esmat G, El-Sayed MH, Hassany M et al. One step closer to elimination of hepatitis C in Egypt. *Lancet Gastroenterol Hepatol* 2018; 3: 665
24. Eckman MH, Ward JW, Sherman KE. Cost effectiveness of universal screening for hepatitis C virus infection in the era of direct-acting, pangenotypic treatment regimens. *Clin Gastroenterol Hepatol* 2019; 17: 930-939 e939
25. Deuffic-Burban S, Huneau A, Verleene A et al. Assessing the cost-effectiveness of hepatitis C screening strategies in France. *J Hepatol* 2018; 69: 785-792
26. Koneru A, Nelson N, Hariri S et al. Increased Hepatitis C Virus (HCV) Detection in Women of Childbearing Age and Potential Risk for Vertical Transmission - United States and Kentucky, 2011-2014. *MMWR Morbidity and mortality weekly report* 2016; 65: 705-710
27. Dibba P, Cholankeril R, Li AA et al. Hepatitis C in Pregnancy. *Diseases* 2018; 6: 31

28. Indolfi G, Easterbrook P, Dusheiko G et al. Hepatitis C virus infection in children and adolescents. *Lancet Gastroenterol Hepatol* 2019; 4: 477-487
29. Saab S, Kullar R, Gounder P. The Urgent Need for Hepatitis C Screening in Pregnant Women: A Call to Action. *Obstetrics & Gynecology* 2020; 135: 773-777
30. Modin L, Arshad A, Wilkes B et al. Epidemiology and natural history of hepatitis C virus infection among children and young people. *J Hepatol* 2019; 70: 371-378
31. Andreone P, Di Marco V, Gaeta GB et al. Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: assessment of an Italian focus group. *Dig Liver Dis* 2019; 51: 915-921
32. Chevaliez S, Pawlotsky JM. New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings. *J Hepatol* 2018; 69: 916-926
33. World Health Organization (WHO). *WHO prequalification of in vitro diagnostics public reports: Hepatitis C assays*, [https://www.who.int/diagnostics\\_laboratory/evaluations/pq-list/hcv/public\\_report/en/](https://www.who.int/diagnostics_laboratory/evaluations/pq-list/hcv/public_report/en/) (2019) Accessed: April 2020.
34. Tang W, Chen W, Amini A et al. Diagnostic accuracy of tests to detect Hepatitis C antibody: a meta-analysis and review of the literature. *BMC Infect Dis* 2017; 17: 695
35. Bregenzer A, Conen A, Knuchel J et al. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade. *Swiss Med Wkly* 2017; 147: w14544
36. Anderson ES, Galbraith JW, Deering LJ et al. Continuum of care for hepatitis C virus among patients diagnosed in the emergency department setting. *Clin Infect Dis* 2017; 64: 1540-1546
37. Parisi MR, Tecco S, Gastaldi G et al. Point-of-care testing for hepatitis C virus infection at alternative and high-risk sites: an Italian pilot study in a dental clinic. *New Microbiol* 2017; 40: 242-245



38. Chiong F, Post J. Opportunistic assessment and treatment of people with hepatitis C virus infection admitted to hospital for other reasons: A prospective cohort study. *Int J Drug Policy* 2019; 65: 50-55
39. Society for Maternal-Fetal Medicine . Electronic address pso, Hughes BL, Page CM et al. Hepatitis C in pregnancy: screening, treatment, and management. *Am J Obstet Gynecol* 2017; 217: B2-B12
40. Morano JP, Zelenev A, Lombard A et al. Strategies for hepatitis C testing and linkage to care for vulnerable populations: point-of-care and standard HCV testing in a mobile medical clinic. *J Community Health* 2014; 39: 922-934
41. Calderon Y, Cowan E, Schramm C et al. HCV and HBV testing acceptability and knowledge among urban emergency department patients and pharmacy clients. *Prev Med* 2014; 61: 29-33
42. Lazarus JV, Picchio C, Dillon JF et al. Too many people with viral hepatitis are diagnosed late - with dire consequences. *Nat Rev Gastroenterol Hepatol* 2019; 16: 451-452
43. Vazquez-Moron S, Ardizzone Jimenez B, Jimenez-Sousa MA et al. Evaluation of the diagnostic accuracy of laboratory-based screening for hepatitis C in dried blood spot samples: A systematic review and meta-analysis. *Sci Rep* 2019; 9: 7316
44. Rege S, Sanchez Y, Marx S et al. PS-066-Patient flow across physician specialties over the course of the hepatitis C care cascade: A real-world analysis from the United States. *Journal of Hepatology* 2019; 70: e40
45. Centre for Disease Analysis. *Web Annex C. Estimates of the coverage of diagnosis and treatment for hepatitis B and C virus infection, by WHO region and income group, 2015. In: Global hepatitis report 2017. Geneva: World Health Organization; 2018 (WHO/CDS/HIV/18.47). <https://apps.who.int/iris/bitstream/handle/10665/277006/WHO-CDS-HIV-18.47-eng.pdf> (2018) Accessed: April 2020.*



46. European Union HCVC. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. *Lancet Gastroenterol Hepatol* 2017; 2: 325-336
47. Hajarizadeh B, Grebely J, McManus H et al. Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment. *J Gastroenterol Hepatol* 2017; 32: 229-236
48. Veterans Health Administration. *Review of Hepatitis C Virus Care within the Veterans Health Administration*, <https://www.va.gov/oig/pubs/VAOIG-17-05297-85.pdf> (2019) Accessed: April 2020.
49. Falade-Nwulia O, McAdams-Mahmoud A, Irvin R et al. Primary care providers knowledge, attitude and practices related to hepatitis C screening and treatment in the oral direct acting antiviral agents era. *J Community Med Health Educ* 2016; 6:
50. American Association for the Study of Liver Diseases (AASLD) IDSoAI. *Simplified HCV Treatment Algorithm for Treatment-Naive Adults Without Cirrhosis*, [https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/AASLD-IDSA\\_HCV-Guidance\\_TxN-Simplified-Tx-No-Cirr\\_c.pdf](https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/AASLD-IDSA_HCV-Guidance_TxN-Simplified-Tx-No-Cirr_c.pdf) (2019) Accessed: April 2020.
51. American Association for the Study of Liver Diseases (AASLD) IDSoAI. *Simplified HCV Treatment Algorithm for Treatment-Naive Adults With Compensated Cirrhosis*, [https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/AASLD-IDSA\\_HCV-Guidance\\_TxN-Simplified-Tx-Comp-Cirr\\_c.pdf](https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/AASLD-IDSA_HCV-Guidance_TxN-Simplified-Tx-Comp-Cirr_c.pdf) (2019) Accessed: April 2020.
52. Wade AJ, Doyle JS, Gane E et al. Outcomes of treatment for hepatitis C in primary care compared to hospital-based care: a randomised controlled trial in people who inject drugs. *Clin Infect Dis* 2019:
53. Beste LA, Glorioso TJ, Ho PM et al. Telemedicine specialty support promotes hepatitis C treatment by primary care providers in the Department of Veterans Affairs. *Am J Med* 2017; 130: 432-438 e433

54. Arora S, Thornton K, Murata G et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. *N Engl J Med* 2011; 364: 2199-2207
55. Kattakuzhy S, Gross C, Emmanuel B et al. Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: A nonrandomized clinical trial. *Ann Intern Med* 2017; 167: 311-318
56. Lee A, Hanson J, Fox P et al. A decentralised, multidisciplinary model of care facilitates treatment of hepatitis C in regional Australia. *J Virus Erad* 2018; 4: 160-164
57. Nasir IA, Yakubu Sa, Mustapha JO. Epidemiology and Synergistic Hepatopathology of Malaria and Hepatitis C Virus Coinfection. *Virology (Auckl)* 2017; 8: 1178122X17724411-11178122X17724411
58. Popping S, Bade D, Boucher C et al. The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals. *J Virus Erad* 2019; 5: 60-66
59. Rhea S, Seña AC, Hilton A et al. Integrated Hepatitis C Testing and Linkage to Care at a Local Health Department Sexually Transmitted Disease Clinic: Determining Essential Resources and Evaluating Outcomes. *Sexually transmitted diseases* 2018; 45: 229-232
60. Cachay ER, Hill L, Ballard C et al. Increasing Hepatitis C treatment uptake among HIV-infected patients using an HIV primary care model. *AIDS Research and Therapy* 2013; 10: 9
61. Bischoff J, Boesecke C, Ingiliz P et al. Has increased rollout of direct acting antiviral therapy decreased the burden of late presentation and advanced liver disease in patients starting hepatitis C virus therapy in Germany? *J Clin Gastroenterol* 2019; 54: 192–199
62. Chirikov VV, Marx SE, Manthana SR et al. Development of a comprehensive dataset of hepatitis C patients and examination of disease epidemiology in the United States, 2013-2016. *Adv Ther* 2018; 35: 1087-1102
63. Trivedi HD, Patwardhan VR, Malik R. Chronic hepatitis C infection - Noninvasive assessment of liver fibrosis in the era of direct acting antivirals. *Dig Liver Dis* 2019; 51: 183-189

64. Norton BL, Akiyama MJ, Zamor PJ et al. Treatment of chronic hepatitis C in patients receiving opioid agonist therapy: A review of best practice. *Infect Dis Clin North Am* 2018; 32: 347-370
65. Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. *Clin Infect Dis* 2013; 57 Suppl 2: S56-61
66. Fontana RJ, Lens S, McPherson S et al. Efficacy and safety of 8 weeks of glecaprevir/pibrentasvir in treatment-naïve adults with HCV genotype 1–6 and aspartate aminotransferase to platelet ratio index (APRI)  $\leq 1$ . *Hepatology* 2018; 68: 388A-389A (abstract and poster presentation #653)
67. Gupta N, Kateera F, Desalegn H et al. Is resistance to direct-acting antivirals in sub-Saharan Africa a threat to HCV elimination? Recommendations for action. *Journal of Hepatology* 2019; 72: 583–584
68. World Health Organization W. *Progress report on access to hepatitis C treatment: Focus on overcoming barriers in low- and middle-income countries*, <https://www.who.int/hepatitis/publications/hep-c-access-report-2018/en/> (2018) Accessed: April 2020.
69. Marshall AD, Pawlotsky JM, Lazarus JV et al. The removal of DAA restrictions in Europe - One step closer to eliminating HCV as a major public health threat. *J Hepatol* 2018; 69: 1188-1196
70. National Viral Hepatitis Roundtable. *Hepatitis C: The state of Medicaid access: 2017 National Summary Report, October 23, 2017*, [https://stateofhepc.org/wp-content/uploads/2017/10/State-of-HepC\\_2017\\_FINAL.pdf](https://stateofhepc.org/wp-content/uploads/2017/10/State-of-HepC_2017_FINAL.pdf) (Accessed: April 2020).
71. Cunningham EB, Amin J, Feld JJ et al. Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. *Int J Drug Policy* 2018; 62: 14-23
72. Kattakuzhy S, Mathur P, Gross C et al. High SVR in PWID with HCV despite imperfect medication adherence: Data from the Anchor study. *Hepatology* 2018; 68: 12A (abstract18)

73. [Anonymous]. *The National Academies of Sciences, Engineering, and Medicine. A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report*,  
<http://www.nationalacademies.org/hmd/reports/2017/national-strategy-for-the-elimination-of-hepatitis-b-and-c.aspx> (2017) Accessed: April 2020.
74. AbbVie. *Mavyret (glecaprevir/pibrentasvir) US Prescribing Information (September 2019)*,  
[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2018/209394s002lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209394s002lbl.pdf) (2019)  
Accessed: April 2020
75. Gilead. *Epclusa (sofosbuvir/velpatasvir) US Prescribing Information*,  
[https://www.gilead.com/-/media/files/pdfs/medicines/liver-disease/epclusa/epclusa\\_pi.pdf](https://www.gilead.com/-/media/files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.pdf)  
(2020) Accessed: April 2020.
76. Republic of Rwanda Ministry of Health. *Rwanda's fight in the elimination of Hepatitis C Virus*,  
[http://moh.gov.rw/index.php?id=19&tx\\_news\\_pi1%5Bnews%5D=76&tx\\_news\\_pi1%5Bday%5D=1&tx\\_news\\_pi1%5Bmonth%5D=8&tx\\_news\\_pi1%5Byear%5D=2019&cHash=5bd9a53465e639666f11d1b7aa0ea60a](http://moh.gov.rw/index.php?id=19&tx_news_pi1%5Bnews%5D=76&tx_news_pi1%5Bday%5D=1&tx_news_pi1%5Bmonth%5D=8&tx_news_pi1%5Byear%5D=2019&cHash=5bd9a53465e639666f11d1b7aa0ea60a) (2019) Accessed: April 2020.
77. Iyengar S, Tay-Teo K, Vogler S et al. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. *PLoS Med* 2016; 13: e1002032-e1002032
78. Perazzo H, Castro R, Luz PM et al. Effectiveness of generic direct-acting agents for the treatment of hepatitis C: systematic review and meta-analysis. *Bull World Health Organ* 2020; 98: 188-197K
79. VanOpdorp JR, Ferrentino N, Strader DB et al. Utility of laboratory monitoring during hepatitis C treatment with ribavirin-free direct acting antiviral regimens. *J Viral Hepat* 2019; 26: 778–781
80. D'Ambrosio R, Pasulo L, Puoti M et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. *Journal of Hepatology* 2019; 70: 379-387

81. Maasoumy B, Buggisch P, Mauss S et al. Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients. *Liver International* 2018; 38: 1906-1910
82. Cuadrado A, Llerena S, Cobo C et al. Microenvironment eradication of hepatitis C: A novel treatment paradigm. *Am J Gastroenterol* 2018; 113: 1639-1648
83. Dore G, Feld J, Thompson A et al. PS-178-Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study. *Journal of Hepatology* 2019; 70: e110
84. Mutasa-Apollo T, Ford N, Wiens M et al. Effect of frequency of clinic visits and medication pick-up on antiretroviral treatment outcomes: a systematic literature review and meta-analysis. *J Int AIDS Soc* 2017; 20: 21647
85. Welzel TM, Yang M, Sajeev G et al. Assessing patient preferences for treatment decisions for new direct acting antiviral (DAA) therapies for chronic hepatitis C virus infections. *Adv Ther* 2019; 36: 2475-2486
86. Aspinall EJ, Corson S, Doyle JS et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. *Clin Infect Dis* 2013; 57 Suppl 2: S80-89
87. Heffernan A, Cooke GS, Nayagam S et al. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. *Lancet* 2019; 393: 1319-1329
88. Loustaud-Ratti V, Debette-Gratien M, Carrier P. European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift. *World J Hepatol* 2018; 10: 639-644
89. Hepatitis C Virus Infection Consensus Statement Working Group. *Australian recommendations for the management of hepatitis C infection: a consensus statement*, <https://www.asid.net.au/documents/item/1208> (2018) Accessed: April 2020.

**A****B**

# **Simplification of Care for Chronic Hepatitis C Virus Infection**

Jean-Michel Pawlotsky<sup>1</sup>, Christian B. Ramers<sup>2</sup>, John F. Dillon<sup>3</sup>, Jordan J. Feld<sup>4</sup>, Jeffrey V. Lazarus<sup>5</sup>

<sup>1</sup>National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Henri Mondor Hospital, University of Paris-Est, and INSERM U955, 51 avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France; [jean-michel.pawlotsky@aphp.fr](mailto:jean-michel.pawlotsky@aphp.fr)

<sup>2</sup>Division of Infectious Diseases, Department of Medicine, UC San Diego School of Medicine, 9500 Gilman Dr. La Jolla, CA, 92093, CA, United States; [christianr@fhcsd.org](mailto:christianr@fhcsd.org)

<sup>3</sup>Ward 2, Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, UK, DD1 9SY; [j.dillon@nhs.net](mailto:j.dillon@nhs.net)

<sup>4</sup>Toronto Centre for Liver Disease, University Health Network, Sandra Rotman Centre for Global Health 200 Elizabeth Street, 9EB-240 Toronto, Canada, ON M5G 2C4; [jordan.feld@uhn.ca](mailto:jordan.feld@uhn.ca)

<sup>5</sup>Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Calle del Rossellón 132, ES-08036, Barcelona, Spain; [jeffrey.lazarus@isglobal.org](mailto:jeffrey.lazarus@isglobal.org)

## **Correspondence to:**

Professor Jean-Michel Pawlotsky  
National Reference Center for Viral Hepatitis B, C and D  
Department of Virology,  
Henri Mondor Hospital  
51 Avenue du Maréchal de Lattre de Tassigny,



25 94010 Créteil, France

26 Tel.: +33-1-4981-2827

27 Fax: +33-1-4981-4831

28 Email: [jean-michel.pawlotsky@aphp.fr](mailto:jean-michel.pawlotsky@aphp.fr)

29

30 **Running head: Chronic Hepatitis C Virus Care Simplification**

31 **Keywords: hepatitis C virus, care cascade, screening, diagnosis, treatment**

32 **Word Count: 5749/6000**

33

34

## Abstract

In 2016, the World Health Organization (WHO) set a target for eliminating viral hepatitis as a major public health threat by 2030. However, while today's highly effective and well-tolerated pangenotypic direct-acting antiviral (DAA) regimens have maximized simplification of HCV treatment, there remain a plethora of barriers to HCV screening, diagnosis and linkage to care. As of 2017, only 19% of the estimated 71 million individuals living with chronic hepatitis C virus (HCV) worldwide were diagnosed and in 2015–2016, only 21% of diagnosed individuals had accessed treatment. Simplification and decentralization of the HCV care cascade would bolster patient engagement and support the considerable scale-up needed to achieve WHO targets. Recent developments in HCV screening and diagnosis, together with reduced pre-treatment assessment and on-treatment monitoring requirements, can further streamline the care continuum, ensuring patients are linked to care quickly and earlier in the disease course, and minimize clinic visits.

## Main Concepts and Learning Points

Today's highly effective, well-tolerated, all-oral, direct-acting antiviral combinations for the treatment of chronic hepatitis C virus infection have made elimination of the virus theoretically achievable by the World Health Organization's target of 2030
---

Despite the availability of curative hepatitis C virus treatments, most persons infected with hepatitis C virus remain untreated
--

Recent developments in hepatitis C virus screening and diagnostic procedures, as well as reduced pre-treatment assessments and on-treatment monitoring requirements, can simplify the hepatitis c virus continuum of care
---

Simplification of the hepatitis c virus care cascade would facilitate patient engagement and support the current concerted effort towards hepatitis c virus elimination
---

The journey from hepatitis c virus screening to cure can be achieved in as few as five steps and in as little as 20 to 24 weeks
---

## Introduction

The availability of highly effective, well-tolerated, all-oral, direct-acting antiviral (DAA) combinations for the treatment of chronic hepatitis C virus (HCV) infection has made the elimination of HCV a theoretically achievable goal within the next decade.[1] In May 2016, the World Health Organization (WHO) adopted their “Global Health Sector Strategy on Viral Hepatitis, 2016–2021,” which aims to eliminate viral hepatitis as a major public health threat by 2030 by reducing new chronic infections by 90% and mortality by 65%. To achieve this goal, 90% of individuals with chronic HCV infection need to be diagnosed, and 80% of those need to be treated.[2] Worldwide, however, the majority of people infected with HCV are not diagnosed and, therefore, remain untreated. In 2017, an estimated 71 million individuals were living with chronic HCV worldwide.[3] Of these, it is thought that only 13.1 million (19%) knew of their infection and only 5 million of those (38%) had accessed treatment by the end of 2017.[3] Simplification of the HCV care cascade, ideally at all steps in the continuum of care, would help to ensure that more patients remain engaged in the care pathway and ultimately support the considerable scale-up needed to achieve WHO targets.[4] In this article, we review the existing care pathway and discuss potential opportunities in which the patient journey from HCV screening to cure could be streamlined.

## Overview of the current HCV care pathway

Depending on the setting, and despite a current concerted effort towards simplification, the current HCV care pathway can be visualized as a sequence of anywhere up to 10 steps ([Fig. 1A](#)), from screening to cure, as advocated by international guidelines for HCV management, such as those from the American Association for the Study of Liver

Diseases (AASLD)/Infectious Diseases Society of America (IDSA),[5] the European Association for the Study of the Liver (EASL),[6] and WHO.[7] The steps can be grouped into three distinct phases: screening and diagnosis, pre-treatment, and treatment and monitoring (including post-treatment follow-up).

### *Screening and Diagnosis*

The screening and diagnosis phase includes screening for the presence of anti-HCV antibodies and confirming active HCV replication. Traditionally, screening of individuals at risk of HCV infection using an anti-HCV antibody test has been widely recommended, with periodic retesting for those at ongoing risk of (re)infection, such as people who inject drugs (PWID).[5-7] However, recent guideline updates have seen the broadening of this recommendation to one-time, routine, opt-out HCV testing for all individuals aged 18 years and older, with some also recommending testing in the prenatal setting during each pregnancy.[3,5,8,9] Other screening strategies include birth cohort testing or screening the general population in areas where HCV seroprevalence is intermediate ( $\geq 2\%$ ) or high ( $\geq 5\%$ ).[6,7] In individuals who are anti-HCV antibody positive, HCV replication is confirmed using a qualitative/quantitative HCV RNA test.[5-7] HCV core antigen detection and quantification may also be used to diagnose acute or chronic HCV infection.[6,7] With both assays, only the presence, not the amount, of marker is used for medical decisions. For payer reimbursement in some regions, namely the United States and Canada, two separate HCV RNA tests at least 6 months apart are required to confirm a diagnosis of chronic HCV infection. Guidelines now recommend that individuals with acute HCV infection are linked to appropriate care with a healthcare provider who will administer comprehensive management, rather than waiting for progression to chronic disease.[5,10]

100

101 *Pre-Treatment Phase*

102           For many patients, the pre-treatment phase includes an initial visit to a specialist  
103 (hepatologist, gastroenterologist, or infectious disease specialist) for pre-treatment  
104 assessments and selection of an appropriate HCV treatment. Prior to treatment initiation, a  
105 series of recommended tests are performed to identify viral and host factors that may  
106 impact the choice of treatment, prognosis, and/or required follow-up. In the DAA era, and  
107 with pangenotypic options available, the number of pre-treatment tests has been reduced;  
108 in particular, viral factors (eg, HCV genotype/subtype, presence of HCV drug resistance–  
109 associated substitutions) that may have previously impacted viral response and, therefore,  
110 treatment choice are not always required. However, it is still generally important to assess  
111 other active infections, such as hepatitis B virus (HBV) or human immunodeficiency virus  
112 (HIV), and confirm HCV genotype where appropriate.[5-7] Furthermore, it is considered  
113 good clinical practice to assess the degree of liver fibrosis in order to inform treatment  
114 decisions.[5-7]

115

116 *Treatment and Monitoring Phase*

117           In most cases, the choice of DAA and treatment duration have been based on HCV  
118 genotype, liver disease severity, and prior HCV treatment status. AASLD/IDSA guidance and  
119 2018 EASL recommendations advocate ribavirin-free DAA regimens, preferably  
120 pangenotypic if available (ie, those effective against the main HCV genotypes 1–6), for HCV  
121 treatment-naïve or -experienced adults without cirrhosis or with compensated cirrhosis.[3]  
122 Ribavirin is required in patients with decompensated cirrhosis.[5,6] In addition, EASL  
123 guidelines recommend combination regimens comprising two rather than three DAAs to

minimize the risk of adverse effects or drug–drug interactions.[6] Finally, WHO guidelines only recommend pangenotypic DAA regimens for all adults with or without cirrhosis.[7]

Although DAAs are generally well-tolerated, patients should be assessed for adverse events or potential drug–drug interactions at each visit or, according to WHO guidelines, at the end of treatment.[5-7] HBV reactivation during or after DAA treatment has been reported in patients who are hepatitis B surface antigen–positive and not receiving HBV antiviral therapy.[5] Therefore, patients meeting criteria for active HBV infection should be started on HBV antiviral therapy. Patients with low or undetectable HBV DNA levels can either receive prophylactic HBV therapy or be monitored for HBV reactivation during and immediately after HCV DAA therapy; HBV therapy should be initiated in patients with evidence of HBV reactivation.[5-7]

The final monitoring step is assessment of HCV cure, defined as a sustained virologic response (SVR; ie, undetectable HCV RNA) 12 weeks after completion of treatment (SVR12).[5-7] Some guidelines suggest SVR at 24 weeks after completion of treatment (SVR24) can also be used to define cure[6,7]; however, because of the high rate of concordance between SVR12 and SVR24 (sensitivity and specificity of 99% and 98%, respectively), the US Food and Drug Administration, and AASLD/IDSA guidelines, have defined HCV cure as SVR12.[5,11] Some patients may require additional monitoring, for instance to minimize drug–drug interactions between HCV DAAs and anti-HIV medications or immunosuppressants that could jeopardize graft success in liver transplant recipients.[5,6] Patients with advanced cirrhosis should also be monitored closely during treatment, and for hepatocellular carcinoma (HCC) after treatment.[5-7]

## **Simplifying the HCV Care Pathway**

The current HCV care pathway is complex and often difficult to navigate for many patients, with multiple office visits, blood draws, assessments, and interactions with different healthcare providers and payers. This level of continuous care can be a particularly challenging barrier in some populations that require specific public health approaches because of a high incidence of HCV, high prevalence of HCV, stigma, discrimination, criminalization or vulnerability, and/or difficulty accessing healthcare services, such that they would benefit from a streamlined care pathway.[7] Examples of such populations include PWID, prisoners, homeless individuals, migrants, those in rural communities with poor access to care, those struggling with mental health or substance use disorders, some groups of men who have sex with men, sex workers, and indigenous populations who are historically less engaged in healthcare. In addition, the current pathway requires high-level laboratory and clinical capabilities to diagnose infection, identify the HCV genotype, assess fibrosis, and monitor treatment. These requirements potentially create barriers for HCV care management.

Based on recent advances in diagnostic techniques and HCV treatments, the current HCV care pathway can be streamlined (**Fig. 1B**), and simplification of care is an increasing focus within the field of HCV treatment.[4] Simplification will potentially have multiple benefits, including better allocation of resources to diagnose and treat more patients (expanding access and coverage), acceleration of treatment initiation (linkage to care), reduction in HCV transmission among high-risk populations (treatment as prevention), improvement in patient adherence, facilitation of task-sharing/patient management by non-specialists, and lowering the long-term medical costs of untreated HCV infection, such as those associated with advanced liver disease, extra-hepatic complications of HCV infection, or liver transplant.

For many patients, the ideal HCV care pathway would involve diagnosis, pre-treatment work up, and treatment initiation in a single day. A US study modeled the impact of a hypothetical “consolidated” HCV care pathway that required at least two visits for patients to receive treatment.[12] In this scenario, a positive anti-HCV test led immediately to an HCV RNA test, HCV genotyping, and fibrosis staging, which took place during a single visit. Referral to a specialist was required only for patients with moderate to advanced fibrosis (METAVIR stage  $\geq$ F2); therefore, an estimated 40% of patients could be managed by their primary care provider. Compared with the current HCV care pathway that requires at least four visits before receiving treatment, the consolidated pathway reduced the percentage of patients lost to follow-up from screening to treatment from 71–76% (depending upon the insurance provider) to 4–5%. Therefore, reducing the steps in the care pathway increased the number of patients who learned of their HCV status, were linked to care, and received HCV treatment. The cost to identify and link to care one additional patient with HCV was \$1586–\$2546 with the current HCV care pathway and \$212–\$548 with the consolidated pathway.[12] However, these findings may not be generalizable to all geographical settings or certain high-risk populations.

### **Simplifying the Screening and Diagnosis Phase**

Screening and diagnostic services need to reach much larger numbers of individuals with HCV infection to achieve the WHO elimination target of 90% diagnosed by 2030. Strategies to increase anti-HCV screening and diagnosis rates include risk factor–based screening, universal screening in specific populations, simplification of sampling using capillary whole blood, dried blood spot (DBS) testing, and point-of-care (PoC) testing using rapid diagnostic tests (RDTs).



## *Screening Programs*

Risk factor–based anti-HCV screening has previously been a prominent feature of international guidelines. However, screening for specific risk factors for HCV infection (ie, risk behaviors or exposures) has largely been unsuccessful because of patients’ reluctance to disclose these risks and provider limitations in collecting risk information.[5] Population-based screening methods may be more successful (ie, identifying and screening populations that have a relatively high prevalence of HCV infection). For example, in the United States, 50% of all HCV infections occur in individuals born between 1945 and 1965; therefore, one-time HCV testing has been recommended in this birth cohort.[13] Nevertheless, screening rates are still low in this population because of, among other reasons, the stigma associated with HCV infection, the asymptomatic course of the disease, the lack of awareness of testing recommendations, and low healthcare engagement of the most at-risk populations.[14]

However, recent guideline updates have seen recommendations for screening broaden to include routine one-time HCV testing for all individuals aged 18 years and older.[3,5,8,9] Practical implementation measures, such as electronic medical record prompts, that have been shown to significantly increase screening rates in individuals born between 1945 and 1965 may help to facilitate universal screening and alleviate any stigma related to the disease. For example, in one study of this demographic group, screening rates increased from 7.6% during the 6 months before their introduction to 72% over the year after their introduction.[15]

PWID have been identified as a priority population for HCV elimination. Worldwide, approximately 40% of people with recent injecting drug use are infected with HCV and 9% of all people living with HCV infection are those who recently injected drugs, with wide

variation among countries.[16] It has been estimated that 43% of all new HCV infections could be prevented over 12 years (2018–2030) if the HCV transmission risk associated with PWID was removed over that period.[17] Uptake of HCV treatment in this group is historically low,[18] despite guideline recommendations to regularly screen PWID for HCV.[5-7] The challenge for screening this population is the lack of engagement with traditional sources of healthcare; therefore, alternative options must be explored. One successful strategy is to integrate HCV screening programs into harm reduction and community outreach facilities, thereby offering a comprehensive “one-stop strategy” at the PoC for HCV screening and diagnosis, treatment initiation, and follow-up. Such approaches have been successfully implemented in several countries including France,[19] Switzerland,[20] and the United States.[21] In Scotland, the launch of the Hepatitis C Action Plan introduced DBS sampling into community drug services to increase access to testing.[22] Between the pre–Action Plan (1999–2006) and Action Plan (2007–2011) periods, the average number of annual tests increased from 67 to 973; the percentage of individuals testing positive for HCV also increased across these periods (from 19% to 38%).

Unfortunately, screening birth cohorts and high-risk populations such as PWID will not find all of the remaining individuals infected with HCV. Achieving WHO elimination targets will require the adoption of broader, simpler screening policies. Different regional strategies will be needed because of the variable global epidemiology of HCV infection.[16] One strategy under consideration is universal anti-HCV screening of all adults. Egypt, which has the highest prevalence of HCV worldwide and access to low-cost generic DAA treatments, has embarked on one such program: following a campaign of targeted screening, all adults aged 18 years and older are now being screened.[23] This approach may be too costly in regions with low HCV prevalence because of the large number of

patients needed to be screened. However, modeling studies in France and the United States have shown universal screening can be cost-effective in low prevalence regions.[24,25] Indeed, the US Preventative Services Task Force has recently updated their recommendations to include HCV screening for all adults 18–79 years of age.[8] Likewise, the US Centers for Disease Control & Prevention (CDC) recently ~~proposed draft~~updated their recommendations to include screening of all adults aged 18 years and older in addition to all pregnant women; except in settings where the prevalence of HCV is less than 0.1%.[9]

HCV screening in pregnancy represents an important opportunity for healthcare provider interaction with women of childbearing age, in whom rates of HCV have been increasing in recent years.[26] The prevalence of HCV antibodies in pregnant women is thought to be 0.1–3.6% worldwide, and some studies suggest that chronic HCV infection is associated with an increased risk for adverse neonatal outcomes.[27] Furthermore, vertical transmission of HCV from mother to child will occur in up to 5% of cases of HCV monoinfection and is a common source of HCV infection in children.[28]

Around 3.5 million children are estimated to be infected globally,[28] representing an important pool of unidentified HCV cases, with as many as 95% of HCV-infected children in the United States of America remaining undiagnosed.[29] In one study including 119 perinatally infected patients, 38% of those aged >33 years had developed cirrhosis, despite the low prevalence of traditional risk factors.[30]

Alternatively, pragmatic approaches to screening strategies, such as random selection or using a hub-and-spoke model as trialed in Italy, can provide a practical compromise between universal and targeted screening.[31]

Regardless of the model employed and populations targeted, screening to identify undiagnosed cases is vital in achieving elimination targets.

## *Virologic Tools to Simplify HCV Screening*

PoC testing provided outside traditional centralized laboratories can be used with the goal of delivering test results to patients during the same visit.[32] PoC testing relies extensively on the use of one of the many RDTs available for anti-HCV antibody detection, several of which are prequalified by WHO.[33] RDTs can be performed in 20 minutes for anti-HCV antibodies using whole blood obtained by venipuncture or finger prick, or oral fluid. Anti-HCV antibody RDTs have excellent sensitivity and specificity compared with ELISA-based laboratory methods (98% and 100%, respectively).[34] RDTs are valuable in high-throughput settings where results are needed quickly, such as prisons and harm reduction programs. An example of the value of RDTs within a harm reduction setting is provided by Bregenzer et al., where the introduction of an anti-HCV antibody RDT led to 23.9% of PWID undergoing HCV screening, compared with only 2% prior to its introduction.[35]

Confirmation of infection after detection of anti-HCV antibodies requires HCV RNA or core antigen testing. A few PoC HCV RNA assays, which generate results from plasma or whole blood within 60 to 90 minutes, are available.[32] The increasing availability of such assays in high-income settings has the potential to transform HCV testing. In low-income countries, providers need to take advantage of the availability of such technologies, which to date have typically been used for HIV or tuberculosis testing.

To meet the WHO goal of identifying 90% of all HCV-infected individuals, PoC testing needs to be implemented into non-traditional settings to capture individuals not actively engaged in healthcare, including emergency departments, obstetric centers, surgical and psychiatric wards, dental clinics, and pharmacies.[36-41] Potential benefits of increased PoC

testing include reducing the number of clinic visits, which may increase screening and treatment rates, and reducing late presentation, which is common in patients with HCV.[42]

Using DBS samples is an alternative method to PoC testing. A few drops of fingerstick whole blood are placed onto a special absorbent filter paper. After desiccation, DBS can be shipped as non-hazardous materials using regular mail or courier services to reference laboratories for anti-HCV antibody and HCV RNA assessments.[32] DBS diagnostic accuracy is high for anti-HCV antibodies (sensitivity, 96.1%; specificity, 99.2%) and HCV RNA (sensitivity, 97.8%; specificity, 99.2%), with no relevant differences in diagnostic accuracy according to the type of test used.[43] DBS has distinct advantages over blood and oral fluid in terms of ease of transport and storage and may be particularly useful in low- and middle-income countries with high HCV prevalence and limited healthcare infrastructure. In high-income countries, DBS could be used where facilities and treatment for PWID or migrant populations are community located and staffed by workers with limited clinical training.

#### *Methods to Improve Linkage to Care*

In addition to increasing screening rates, loss to follow-up between screening and diagnosis must be reduced. Studies in Europe and the United States show that 69% and 47% of screened patients, respectively, did not receive a confirmatory diagnosis of HCV infection.[44,45] Some countries have higher diagnosis rates, particularly those with national screening plans, such as France (74%) and Australia (75%).[46,47] Reinforcing the link between screening and diagnosis will ensure better identification of infected individuals and improve rates of retention in the HCV care pathway. The screening and diagnosis phase will continue to be a two-step process until it becomes more cost-effective to perform a single HCV RNA test to confirm active HCV infection (eg, in areas with very high HCV

prevalence). Alternatively, advances such as reflex testing combine these steps into a single clinic visit.

Reflex HCV RNA testing, in which a positive anti-HCV test triggers an immediate HCV RNA test on the same sample, eliminates an extra visit for a new sample and enables more rapid linkage to care.[12] Reflex HCV RNA testing, as used by the US Veterans Affairs (VA) system,[48] is important in large health systems, with centralized testing where most patients are actively engaged in care and undergoing phlebotomy rather than PoC testing.[48] However, this approach may be suitable for some field-based PoC approaches outlined above. AASLD/IDSA guidelines recommend that harm reduction programs offer anti-HCV testing with reflex or immediate confirmatory HCV RNA testing,[5] 2018 EASL recommendations state that reflex HCV RNA testing should be applied whenever possible,[6] and WHO guidelines include reflex HCV RNA testing as an approach to promote linkage to care in all patients with HCV.[7]

Increases in screening and diagnosis rates will have a limited impact on WHO elimination targets without concomitant improvements in linkage to care. Although specialist referral may be required for some complex cases, most patients could be treated by their primary care provider if the providers were given adequate training.[7] Therefore, the role of the primary care provider is considered critical for expanding access to HCV care, especially in areas of high HCV prevalence.[49] Recently released “Simplified HCV Treatment Algorithms” from AASLD/IDSA reinforce the concept that less complex cases can be successfully managed by primary care providers with less intensive monitoring.[50,51]

Indeed, ~~providing~~ decentralizing HCV treatment to utilize primary care physicians significantly increased treatment uptake in PWID in Australia and New Zealand compared with hospital-based specialist care (75% vs 34%), with significantly higher cure rates (49% vs

30%).[52] Telementoring programs can be used to educate and support non-specialist providers. These programs take advantage of approaches such as videoconferencing and knowledge networks to establish close collaborations between HCV specialists and primary care providers or other healthcare professionals. One such program, the VA-Extension for Community Healthcare Outcomes (ECHO) program, demonstrated an increase in the rate of primary care provider–initiated HCV treatment from 2.5% to 21.4% ( $p<0.01$ ) with program participation.[53] The ECHO model also demonstrated that HCV treatment administered by non-specialist providers was as safe and effective as that provided by specialists in underserved populations.[54] An alternative telementoring approach investigated in the ASCEND study indicates that under specialist oversight, nurse practitioners or primary care physicians only required a short 3-hour training session to treat patients as effectively as specialists.[55] Shifting-Decentralizing HCV care from specialists to primary care providers, as well as other healthcare professionals such as addiction specialists, prison doctors, and advanced practice providers, would simplify the continuum of care and expand access to HCV treatments without compromising outcomes. [56] Furthermore, integrating HCV care pathways with those for common copathologies such as HIV, malaria or sexually transmitted diseases represents another important method for expanding access to HCV diagnosis and treatment[57-59] and can increase HCV diagnosis and treatment uptake. [59,60]

## **Simplifying the Pre-Treatment Phase**

### *Assessing Liver Fibrosis*

Once chronic HCV infection has been confirmed, patients undergo several pre-treatment assessments.[5-7] Staging of liver fibrosis by at least one method is required for all patients prior to treatment to determine the need for post-treatment monitoring (ie, bi-

annual HCC ultrasound screening) in patients with advanced fibrosis (METAVIR score F3) or cirrhosis (METAVIR score F4).[5-7] If advanced fibrosis or cirrhosis is present, these patients should be referred to a specialist provider for their continued care requirements. However, the remaining population with HCV infection is evolving to generally be younger and have milder liver disease,[61,62] which may help to support more non-specialist provider involvement.

Although biopsy was previously used for assessing liver fibrosis, the procedure is invasive and minor complications are common. Alternative, validated and non-invasive methods including serologic, physical, and imaging protocols have replaced biopsy and are preferred to stage liver fibrosis.[63] Simplifying the initial liver fibrosis assessment using non-invasive methods would enable decision-making by non-specialist providers, which would reduce referrals to specialists and improve access to care for patients. This could be particularly impactful for high-risk groups, such as PWID, who may already be managed in a number of health care settings.[64,65]

The calculation of an aspartate aminotransferase (AST)-to-platelet ratio index (APRI) score using AST concentrations and platelet count has excellent negative predictive value and can identify patients not at risk for advanced liver fibrosis who could be easily managed by non-specialist providers.[63] In a prospective study in treatment-naïve patients chronically infected with HCV genotype 1–6 and no history of cirrhosis, APRI  $\leq 1$  was used to select patients for 8 weeks' treatment with the pangenotypic DAA combination glecaprevir/pibrentasvir.[66] The results showed that APRI  $\leq 1$  (mean, 0.41; range, 0.13–1.00) identified patients without cirrhosis who could then be appropriately treated by non-specialist providers. Fibrosis-4 (FIB-4) is another tool that uses a formula based on age, AST, platelets, and alanine aminotransferase to score fibrosis.[63] FibroTest is a laboratory-



387 ordered test using a proprietary formula based on age, gender, and five additional  
388 biomarkers.[63] Transient elastography (eg, FibroScan®) measures liver stiffness to assess  
389 fibrosis; in addition, other physical technologies have been developed to assess liver  
390 fibrosis.[63] FibroScan and FibroTest use may be restricted by cost and availability in  
391 resource-limited settings. AASLD/IDSA guidelines recommend liver biopsy and/or non-  
392 invasive markers to evaluate liver fibrosis in patients with chronic HCV infection.[5] The new  
393 simplified algorithms from AASLD/IDSA emphasize the utility of non-invasive tests for  
394 fibrosis assessment.[50,51] EASL and WHO guidelines recommend non-invasive methods,  
395 especially APRI and FIB-4, outside specialty clinics in resource-limited settings.[6,7]

396

#### 397 *HCV Genotype Determination*

398 With the introduction of pangenotypic DAAs, some guidelines consider that the need  
399 for HCV genotyping is reduced, particularly where tests are not available or not affordable,  
400 or to improve access by simplifying the care pathway.[5-7] However, identifying patients  
401 infected with genotype 3, particularly those who have cirrhosis, remains important because  
402 SVR rates can be impacted by prior HCV treatment experience or the presence of NS5A  
403 inhibitor resistance—associated substitutions at baseline.[5-7] Longer treatment durations,  
404 baseline resistance testing, or the addition of a third drug (eg, a DAA with another target or  
405 ribavirin) may be required in patients with HCV genotype 3 infection and cirrhosis. The  
406 decision to identify the HCV genotype may ultimately be one of cost-effectiveness (ie,  
407 relative cost of regimens without genotype 3 restrictions) and the epidemiologic profile of  
408 endemic HCV genotypes within specific regions. WHO guidelines stipulate that where HCV  
409 genotype 3 prevalence is <5%, genotyping could be excluded and a uniform pangenotypic  
410 treatment duration used.[7]

However, the prevalence of other potentially difficult-to-treat genotypes such as non-1a/b subtypes of GT1 or non-4a/d subtypes of GT4 are increasing worldwide, largely driven by migration from areas of high endemicity for these subtypes, such as sub-Saharan Africa (SSA).[67] These subtypes are associated with higher failure rates to earlier NS5A inhibitors than other subtypes, with sofosbuvir/velpatasvir/voxilaprevir the only currently approved re-treatment option for those failing initial NS5A-based regimens.[67] This potentially poses a barrier to re-treatment success, as there is limited routine access to this therapy in SSA. Furthermore, settings that cannot access this treatment rely on viral sequencing to inform decision making regarding the most suitable alternative treatment options, but this is also not routinely available in SSA. It will therefore be crucial for settings such as these to increase access to newer pangenotypic regimens, as well as testing and documenting patient genotypes and resistance profiles, in order to monitor the success of first- and second-line HCV treatments.[67]

## **Simplifying the Treatment and Monitoring Phase**

### *Treatment*

Despite the availability of curative HCV treatments, most persons infected with HCV remain untreated.[68] International guidelines recommend that all persons diagnosed with chronic HCV infection should be considered for treatment.[5-7] Adopting a “treat all” approach helps to simplify clinical decision-making; streamline patient management; reduce transmission, morbidity, and mortality; and, ultimately, furthers progress towards WHO elimination targets.

Access restrictions to HCV treatment remain a significant barrier to care in many countries.[69,70] Depending upon the country or healthcare system, access can be

restricted by one or more of the following: high cost, the degree of liver disease (eg, only patients with progressive liver disease [METAVIR stage  $\geq$ F2] can receive DAAs), the prescribing physician (eg, only specialists can prescribe DAAs), or recent illicit drug or alcohol abuse (eg, only patients enrolled in an addiction management program or with demonstrated sobriety can receive DAAs).[69,70] Most restrictions are not evidence-based or supported by guidelines. For example, guidelines state that recent or active injection drug use is not a contraindication to HCV therapy.[5-7] Numerous studies have demonstrated a lack of impact on treatment adherence and high cure rates with DAAs among recent or active drug users.[71,72] Although these restrictions are slowly being lifted in the United States, over 30 state Medicaid plans still have prescriber and sobriety restrictions in place, and ~15 states have fibrosis score restrictions; removing these will improve access to HCV treatment for all patients and is a key recommendation in the US National Strategy to eliminate viral hepatitis.[69,70,73]

The latest DAA combinations have transformed the treatment landscape for chronic HCV infection, offering high cure rates with favorable safety profiles.[7] The fixed-dose DAA combinations glecaprevir/pibrentasvir and sofosbuvir/velpatasvir are pangenotypic, well-tolerated, have virologic cure rates >95%, and treatment courses of 8–12 weeks for most patients.[6,7,74,75]

~~In addition,~~Improving access to HCV treatment worldwide is vital, and in low-to-middle income countries, generic formulations of approved HCV treatments represent an important step towards making HCV elimination an achievable goal.[68] Globally, over 60% of people with HCV infection live in countries with access to affordable generic DAAs,[68] such as generic formulations of sofosbuvir and daclatasvir, also considered pangenotypic, ~~are now widely available in low- and middle-income countries~~ at costs as low as

approximately US \$60 per 12-week supply.[76] Many of these countries have negotiated discounts from manufacturers to help provide universal access to HCV treatment with minimal financial contributions required by patients.[77]

These generic formulations provide a viable option for HCV treatment, as a recent systematic review and meta-analysis of the effectiveness of generic formulations demonstrated equivalent outcomes between generic and licenced DAA formulations in the treatment of HCV.[78]

-These treatment profiles of the pangenotypic DAAs support the practicality of a “treat all” approach and have already helped to streamline the HCV care pathway by simplifying treatment choice.[6,7] However there is further room for expansion to include indications for children under the age of 12 years, who represent an important population to target to achieve elimination efforts. Indeed, AASLD/IDSA guidelines state that the approval of additional DAA regimens for children aged 3–11 years is anticipated in the near future.[5] and sofosbuvir/velpatasvir has recently been approved for use in children from 6 years of age.[75]

#### *On-Treatment Monitoring*

There appears to be no requirement for on-treatment monitoring for virologic efficacy, given the very high cure rates with current DAA combinations, and steps towards simplification with regards to this aspect of HCV treatment have already been made. AASLD/IDSA guidelines previously recommended that HCV RNA viral load was assessed 4 weeks after treatment initiation, 12 weeks after therapy completion (SVR12), and as a consideration at the end of treatment.[5] However, evidence suggests HCV RNA measurements at 4 weeks and at the end of treatment are unnecessary because they are

not predictive of SVR12. In a retrospective review of 208 patients infected with HCV receiving DAAs, no difference was reported in SVR12 rates between patients with detectable and undetectable HCV RNA at week 4 (96.5% vs 97.5%;  $p=0.69$ ).[79] These results have been replicated irrespective of treatment regimen or duration.[80,81] AASLD/IDSA guidelines have recently been updated to dispense with 4-week HCV RNA viral load assessment, now recommending testing only at 12 or more weeks post-treatment completion.[5] Furthermore, 2018 EASL recommendations advocate HCV RNA viral load testing at 12 or 24 weeks post-treatment only but state SVR assessment is dispensable, given the high cure rates expected with pangenotypic regimens.[6] WHO recommends viral load testing at 12 or 24 weeks post-treatment.[7] Patients at risk for reinfection should be tested for SVR12 and yearly thereafter whenever possible.[6]

Another strategy aimed at reducing the reliance on clinic visits and simplifying on-treatment patient monitoring is telemedicine (or telecare). Telemonitoring or teleconsulting programs, which use telephone contact instead of clinic visits, can be used to ensure medication adherence and monitor for adverse events and potential drug–drug interactions. These programs have been successful in underserved populations, such as prisoners.[82] Simplified HCV treatment monitoring via telephone calls versus standard clinic visits was assessed in the SMART-C study, and no differences were seen in virologic or safety outcomes in “easy-to-manage” patients.[83] Taken together with the simplicity, safety, and effectiveness of the latest DAA regimens, measures aimed at reducing clinic visits, especially in high prevalence settings, will relieve the burden on healthcare systems.[84] These strategies will facilitate the retention of patients in care, supporting patients’ preferences for treatment attributes that offer more convenience and require less disruption to daily life (eg, shorter treatment duration and fewer office visits).[85]

In the past, concerns regarding low treatment adherence to interferon-based therapies in PWID meant that additional on-treatment monitoring was warranted.[64,86] However, in the DAA era, evidence suggests that treatment adherence and SVR rates are high in PWID. In the SIMPLIFY study, median adherence to sofosbuvir/velpatasvir for 12 weeks was 94% in PWID with recent injection drug use ( $\leq 6$  months), with 32% of patients considered non-adherent ( $< 90\%$  adherence).[71] Although adherence decreased during therapy, similarly high SVR12 rates were seen in PWID who were adherent ( $\geq 90\%$  of doses received) and non-adherent (94% vs 94%,  $p=0.944$ ).[71] In the ongoing ANCHOR study, in which 97 PWID with recent injection drug use ( $\leq 3$  months) received sofosbuvir/velpatasvir for 12 weeks, SVR12 was achieved by 90% of PWID who attended the week 24 visit.[72] SVR12 rates were unaffected by treatment interruptions that delayed the anticipated date for end of treatment, providing the treatment course was completed.[72] Additional monitoring for treatment adherence in PWID is no longer warranted; instead, pre-therapeutic education and on-treatment support delivered via a decentralized multidisciplinary care approach are important for successful treatment in PWID.

507

#### 508 **Status: Simplifying the HCV Care Pathway**

509         Simplifying the diagnosis, treatment, and monitoring of patients with chronic HCV  
510 infection has improved the prospects for scaling-up the management of patients by primary  
511 care providers and other non-specialist healthcare professionals to further progress towards  
512 achieving the WHO goal of HCV elimination.[87] AASLD/IDSA acknowledge that treatment  
513 simplification could expand the number of healthcare providers who can prescribe HCV  
514 therapy and increase the number of individuals who are treated.[5] EASL recommendations  
515 are also comprehensive but propose that simplified HCV care pathways are now possible

using a pangenotypic DAA regimen for 12 weeks.[6] Recent label updates mean that treatment-naïve patients without cirrhosis or with compensated cirrhosis can now both receive glecaprevir/pibrentasvir for 8 weeks. The only assessments required are to confirm chronic HCV infection and advanced fibrosis or cirrhosis (using non-invasive markers) and establish possible drug–drug interactions. Genotyping can be dispensed with, and SVR12 assessment is not required in, patients who are adherent and not at high risk for reinfection.[6] WHO also has specific recommendations to support their “treat all and use pangenotypic DAAs” recommendation, including simplified treatment pathways and decentralization of testing and treatment services at the primary care level.[7] Simpler HCV care pathways to encourage HCV testing and treatment at the primary care level have been successful in expanding treatment in France[88] and Australia,[89] for example.

## **Conclusions**

Today’s highly effective, safe, and well-tolerated pangenotypic DAA regimens have maximized the opportunity to simplify treatment strategies in the HCV care pathway. Recent developments in HCV screening and diagnostic procedures, together with lower requirements for pre-treatment assessments and on-treatment monitoring, can further streamline the continuum of care, ensuring more patients are linked to care quickly and earlier in the disease course, and with minimal clinic visits. These advances also allow HCV treatment to be prescribed by non-specialist providers, which can reduce overall healthcare costs and further support efforts towards meeting the WHO viral hepatitis elimination goal. Patients and healthcare providers should both be motivated to embark on a simplified HCV care pathway by knowing that, if diagnosed with chronic HCV, the journey from screening to cure can be achieved in as few as five steps and in as little as 20 to 24 weeks.

## Acknowledgements

Medical writing support was provided by Paul MacCallum, PhD, and Heather Shawcross, PhD, of Fishawack Communications, Ltd, and funded by AbbVie. AbbVie funded the publication and participated in the writing, reviewing, and approval of the publication. All authors have had access to relevant data and participated in the drafting, review, and approval of this publication. Eric Crown, PhD, Doug Dylla, PhD, and Dimitri Semizarov, PhD, all of AbbVie Inc, also reviewed and provided feedback on the manuscript.

## Disclosures

**Jean-Michel Pawlotsky:** research grants from Abbot and Vela Diagnostics; advisor for Abbvie, Gilead, GlaxoSmithKline, Merck, Regulus, and Siemens Healthcare; speaker for Abbvie and Gilead.

**Christian B. Ramers:** research grants from AbbVie, Gilead; consulting/speaking fees from AbbVie, Gilead, Merck, Viiv outside of the published work.

**John F. Dillon:** research grants and personal fees from AbbVie, Janssen, Roche, Gilead Sciences, and MSD; grants from CEPHEID, Genedrive, and GlaxoSmithKline, outside the submitted work.

**Jordan J. Feld:** research grants for Abbvie, Gilead, Janssen, and Wako/Fujifilm; consulting for Abbvie, Gilead, Enanta, Janssen, and Roche

**Jeffrey V. Lazarus:** research grants and personal fees from AbbVie, Gilead Sciences and MSD; personal fees from CEPHEID, GlaxoSmithKline, Intercept, and Janssen, outside the submitted work.



**Fig. 1. Overview of the HCV care cascade (A) the traditional care cascade, and (B) a potentially simplified HCV care cascade for treatment-naïve patients without cirrhosis managed in a primary care setting.**

\*Pre-treatment assessments previously recommended by AASLD/IDSA and EASL: HCV genotype and subtype; HCV viral load; fibrosis staging; HBV co-infection; HIV co-infection; complete blood count; international normalized ratio; hepatic function panel; estimated glomerular filtration rate; potential drug-drug interactions.

†On-treatment monitoring previously recommended by AASLD/IDSA: HCV viral load; creatinine level; estimated glomerular filtration rate; hepatic function panel.

‡On-treatment monitoring previously recommended by WHO: Routine laboratory monitoring for treatment toxicity.

§Post-SVR12 monitoring recommended by AASLD/IDSA and EASL: surveillance for hepatocellular carcinoma by twice-yearly ultrasound examination in patients with advanced fibrosis (ie, Metavir stage F3 or F4).

\*¶With reflex testing, screening and diagnosis can be combined to enable confirmatory HCV diagnosis with fewer patient visits. AASLD/IDSA, American Association for the Study of Liver Diseases/Infectious Diseases Society of America; EASL, European Association for the Study of the Liver; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; RNA, ribonucleic acid; SVR12, sustained virologic response 12 weeks after completion of treatment; WHO, World Health Organization

## References

1. Cooke GS, Andrieux-Meyer I, Applegate TL et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. *Lancet Gastroenterol Hepatol* 2019; 4: 135-184
2. World Health Organization (WHO). *Global health sector strategy on viral hepatitis, 2016–2021: Towards ending viral hepatitis*, <https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf;jsessionid=3353B8BE60FB5081680122276F404913?sequence=1> (2016) Accessed: April 2020.
3. World Health Organization (WHO). *Hepatitis C: key facts*, <https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-c> (2019) Accessed: April 2020.
4. Lazarus JV, Pericàs JM, Picchio C et al. We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. *Journal of Internal Medicine* 2019; 286: 503-525
5. American Association for the Study of Liver Diseases (AASLD) IDSoAI. *HCV guidance: Recommendations for testing, managing, and treating hepatitis C*, [www.hcvguidelines.org](http://www.hcvguidelines.org) (2019) Accessed: April 2020.
6. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. *J Hepatol* 2018; 69: 461-511
7. World Health Organization (WHO). *Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection*, <https://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2018/en/> (2018) Accessed: April 2020.
8. US Preventive Services Task Force. *Hepatitis C Virus Infection in Adolescents and Adults: Screening*,

<https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/hepatitis-c-screening1> (2020) Accessed: April 2020.

9. Centers for Disease Control. CDC Recommendations for Hepatitis C Screening Among Adults — United States, 2020. *MMWR Morbidity and mortality weekly report* 2020; 69: 1–18
10. European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. *J Hepatol* 2011; 55: 245-264
11. Mishra P, Murray J, Birnkrant D. Direct-acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: Scientific and regulatory approaches to clinical trial designs. *Hepatology* 2015; 62: 1298-1303
12. Mulligan K, Sullivan J, Yoon L et al. Evaluating HCV screening, linkage to care, and treatment across insurers. *Am J Manag Care* 2018; 24: e257-e264
13. Smith BD, Morgan RL, Beckett GA et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. *MMWR Recomm Rep* 2012; 61: 1-32
14. Jemal A, Fedewa SA. Recent hepatitis C virus testing patterns among baby boomers. *Am J Prev Med* 2017; 53: e31-e33
15. Konerman MA, Thomson M, Gray K et al. Impact of an electronic health record alert in primary care on increasing hepatitis c screening and curative treatment for baby boomers. *Hepatology* 2017; 66: 1805-1813
16. Grebely J, Larney S, Peacock A et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. *Addiction* 2019; 114: 150-166
17. Trickey A, Fraser H, Lim AG et al. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. *Lancet Gastroenterol Hepatol* 2019; 4: 435-444

18. Iversen J, Grebely J, Topp L et al. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011. *J Viral Hepat* 2014; 21: 198-207
19. Delile JM, de Ledinghen V, Jauffret-Roustide M et al. Hepatitis C virus prevention and care for drug injectors: the French approach. *Hepatol Med Policy* 2018; 3: 7
20. Scherz N, Bruggmann P, Brunner N. Direct-acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatment. *Int J Drug Policy* 2018; 62: 74-77
21. Akiyama MJ, Norton BL, Arnsten JH et al. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial. *Ann Intern Med* 2019; 170: 594-603
22. McLeod A, Weir A, Aitken C et al. Rise in testing and diagnosis associated with Scotland's Action Plan on Hepatitis C and introduction of dried blood spot testing. *J Epidemiol Community Health* 2014; 68: 1182-1188
23. Esmat G, El-Sayed MH, Hassany M et al. One step closer to elimination of hepatitis C in Egypt. *Lancet Gastroenterol Hepatol* 2018; 3: 665
24. Eckman MH, Ward JW, Sherman KE. Cost effectiveness of universal screening for hepatitis C virus infection in the era of direct-acting, pangenotypic treatment regimens. *Clin Gastroenterol Hepatol* 2019; 17: 930-939 e939
25. Deuffic-Burban S, Huneau A, Verleene A et al. Assessing the cost-effectiveness of hepatitis C screening strategies in France. *J Hepatol* 2018; 69: 785-792
26. Koneru A, Nelson N, Hariri S et al. Increased Hepatitis C Virus (HCV) Detection in Women of Childbearing Age and Potential Risk for Vertical Transmission - United States and Kentucky, 2011-2014. *MMWR Morbidity and mortality weekly report* 2016; 65: 705-710
27. Dibba P, Cholankeril R, Li AA et al. Hepatitis C in Pregnancy. *Diseases* 2018; 6: 31

28. Indolfi G, Easterbrook P, Dusheiko G et al. Hepatitis C virus infection in children and adolescents. *Lancet Gastroenterol Hepatol* 2019; 4: 477-487
29. Saab S, Kullar R, Gounder P. The Urgent Need for Hepatitis C Screening in Pregnant Women: A Call to Action. *Obstetrics & Gynecology* 2020; 135: 773-777
30. Modin L, Arshad A, Wilkes B et al. Epidemiology and natural history of hepatitis C virus infection among children and young people. *J Hepatol* 2019; 70: 371-378
31. Andreone P, Di Marco V, Gaeta GB et al. Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: assessment of an Italian focus group. *Dig Liver Dis* 2019; 51: 915-921
32. Chevaliez S, Pawlotsky JM. New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings. *J Hepatol* 2018; 69: 916-926
33. World Health Organization (WHO). *WHO prequalification of in vitro diagnostics public reports: Hepatitis C assays*, [https://www.who.int/diagnostics\\_laboratory/evaluations/pq-list/hcv/public\\_report/en/](https://www.who.int/diagnostics_laboratory/evaluations/pq-list/hcv/public_report/en/) (2019) Accessed: April 2020.
34. Tang W, Chen W, Amini A et al. Diagnostic accuracy of tests to detect Hepatitis C antibody: a meta-analysis and review of the literature. *BMC Infect Dis* 2017; 17: 695
35. Bregenzer A, Conen A, Knuchel J et al. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade. *Swiss Med Wkly* 2017; 147: w14544
36. Anderson ES, Galbraith JW, Deering LJ et al. Continuum of care for hepatitis C virus among patients diagnosed in the emergency department setting. *Clin Infect Dis* 2017; 64: 1540-1546
37. Parisi MR, Tecco S, Gastaldi G et al. Point-of-care testing for hepatitis C virus infection at alternative and high-risk sites: an Italian pilot study in a dental clinic. *New Microbiol* 2017; 40: 242-245

38. Chiong F, Post J. Opportunistic assessment and treatment of people with hepatitis C virus infection admitted to hospital for other reasons: A prospective cohort study. *Int J Drug Policy* 2019; 65: 50-55
39. Society for Maternal-Fetal Medicine . Electronic address pso, Hughes BL, Page CM et al. Hepatitis C in pregnancy: screening, treatment, and management. *Am J Obstet Gynecol* 2017; 217: B2-B12
40. Morano JP, Zelenev A, Lombard A et al. Strategies for hepatitis C testing and linkage to care for vulnerable populations: point-of-care and standard HCV testing in a mobile medical clinic. *J Community Health* 2014; 39: 922-934
41. Calderon Y, Cowan E, Schramm C et al. HCV and HBV testing acceptability and knowledge among urban emergency department patients and pharmacy clients. *Prev Med* 2014; 61: 29-33
42. Lazarus JV, Picchio C, Dillon JF et al. Too many people with viral hepatitis are diagnosed late - with dire consequences. *Nat Rev Gastroenterol Hepatol* 2019; 16: 451-452
43. Vazquez-Moron S, Ardizzone Jimenez B, Jimenez-Sousa MA et al. Evaluation of the diagnostic accuracy of laboratory-based screening for hepatitis C in dried blood spot samples: A systematic review and meta-analysis. *Sci Rep* 2019; 9: 7316
44. Rege S, Sanchez Y, Marx S et al. PS-066-Patient flow across physician specialties over the course of the hepatitis C care cascade: A real-world analysis from the United States. *Journal of Hepatology* 2019; 70: e40
45. Centre for Disease Analysis. *Web Annex C. Estimates of the coverage of diagnosis and treatment for hepatitis B and C virus infection, by WHO region and income group, 2015. In: Global hepatitis report 2017. Geneva: World Health Organization; 2018 (WHO/CDS/HIV/18.47). <https://apps.who.int/iris/bitstream/handle/10665/277006/WHO-CDS-HIV-18.47-eng.pdf> (2018) Accessed: April 2020.*

46. European Union HCVC. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. *Lancet Gastroenterol Hepatol* 2017; 2: 325-336
47. Hajarizadeh B, Grebely J, McManus H et al. Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment. *J Gastroenterol Hepatol* 2017; 32: 229-236
48. Veterans Health Administration. *Review of Hepatitis C Virus Care within the Veterans Health Administration*, <https://www.va.gov/oig/pubs/VAOIG-17-05297-85.pdf> (2019) Accessed: April 2020.
49. Falade-Nwulia O, McAdams-Mahmoud A, Irvin R et al. Primary care providers knowledge, attitude and practices related to hepatitis C screening and treatment in the oral direct acting antiviral agents era. *J Community Med Health Educ* 2016; 6:
50. American Association for the Study of Liver Diseases (AASLD) IDSoAI. *Simplified HCV Treatment Algorithm for Treatment-Naive Adults Without Cirrhosis*, [https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/AASLD-IDSA\\_HCV-Guidance\\_TxN-Simplified-Tx-No-Cirr\\_c.pdf](https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/AASLD-IDSA_HCV-Guidance_TxN-Simplified-Tx-No-Cirr_c.pdf) (2019) Accessed: April 2020.
51. American Association for the Study of Liver Diseases (AASLD) IDSoAI. *Simplified HCV Treatment Algorithm for Treatment-Naive Adults With Compensated Cirrhosis*, [https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/AASLD-IDSA\\_HCV-Guidance\\_TxN-Simplified-Tx-Comp-Cirr\\_c.pdf](https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/AASLD-IDSA_HCV-Guidance_TxN-Simplified-Tx-Comp-Cirr_c.pdf) (2019) Accessed: April 2020.
52. Wade AJ, Doyle JS, Gane E et al. Outcomes of treatment for hepatitis C in primary care compared to hospital-based care: a randomised controlled trial in people who inject drugs. *Clin Infect Dis* 2019:
53. Beste LA, Glorioso TJ, Ho PM et al. Telemedicine specialty support promotes hepatitis C treatment by primary care providers in the Department of Veterans Affairs. *Am J Med* 2017; 130: 432-438 e433

54. Arora S, Thornton K, Murata G et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. *N Engl J Med* 2011; 364: 2199-2207
55. Kattakuzhy S, Gross C, Emmanuel B et al. Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: A nonrandomized clinical trial. *Ann Intern Med* 2017; 167: 311-318
56. Lee A, Hanson J, Fox P et al. A decentralised, multidisciplinary model of care facilitates treatment of hepatitis C in regional Australia. *J Virus Erad* 2018; 4: 160-164
57. Nasir IA, Yakubu Sa, Mustapha JO. Epidemiology and Synergistic Hepatopathology of Malaria and Hepatitis C Virus Coinfection. *Virology (Auckl)* 2017; 8: 1178122X17724411-11178122X17724411
58. Popping S, Bade D, Boucher C et al. The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals. *J Virus Erad* 2019; 5: 60-66
59. Rhea S, Seña AC, Hilton A et al. Integrated Hepatitis C Testing and Linkage to Care at a Local Health Department Sexually Transmitted Disease Clinic: Determining Essential Resources and Evaluating Outcomes. *Sexually transmitted diseases* 2018; 45: 229-232
60. Cachay ER, Hill L, Ballard C et al. Increasing Hepatitis C treatment uptake among HIV-infected patients using an HIV primary care model. *AIDS Research and Therapy* 2013; 10: 9
61. Bischoff J, Boesecke C, Ingiliz P et al. Has increased rollout of direct acting antiviral therapy decreased the burden of late presentation and advanced liver disease in patients starting hepatitis C virus therapy in Germany? *J Clin Gastroenterol* 2019; 54: 192–199
62. Chirikov VV, Marx SE, Manthana SR et al. Development of a comprehensive dataset of hepatitis C patients and examination of disease epidemiology in the United States, 2013-2016. *Adv Ther* 2018; 35: 1087-1102
63. Trivedi HD, Patwardhan VR, Malik R. Chronic hepatitis C infection - Noninvasive assessment of liver fibrosis in the era of direct acting antivirals. *Dig Liver Dis* 2019; 51: 183-189



64. Norton BL, Akiyama MJ, Zamor PJ et al. Treatment of chronic hepatitis C in patients receiving opioid agonist therapy: A review of best practice. *Infect Dis Clin North Am* 2018; 32: 347-370
65. Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. *Clin Infect Dis* 2013; 57 Suppl 2: S56-61
66. Fontana RJ, Lens S, McPherson S et al. Efficacy and safety of 8 weeks of glecaprevir/pibrentasvir in treatment-naïve adults with HCV genotype 1–6 and aspartate aminotransferase to platelet ratio index (APRI)  $\leq 1$ . *Hepatology* 2018; 68: 388A-389A (abstract and poster presentation #653)
67. Gupta N, Kateera F, Desalegn H et al. Is resistance to direct-acting antivirals in sub-Saharan Africa a threat to HCV elimination? Recommendations for action. *Journal of Hepatology* 2019; 72: 583–584
68. World Health Organization W. *Progress report on access to hepatitis C treatment: Focus on overcoming barriers in low- and middle-income countries*, <https://www.who.int/hepatitis/publications/hep-c-access-report-2018/en/> (2018) Accessed: April 2020.
69. Marshall AD, Pawlotsky JM, Lazarus JV et al. The removal of DAA restrictions in Europe - One step closer to eliminating HCV as a major public health threat. *J Hepatol* 2018; 69: 1188-1196
70. National Viral Hepatitis Roundtable. *Hepatitis C: The state of Medicaid access: 2017 National Summary Report, October 23, 2017*, [https://stateofhepc.org/wp-content/uploads/2017/10/State-of-HepC\\_2017\\_FINAL.pdf](https://stateofhepc.org/wp-content/uploads/2017/10/State-of-HepC_2017_FINAL.pdf) (Accessed: April 2020).
71. Cunningham EB, Amin J, Feld JJ et al. Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. *Int J Drug Policy* 2018; 62: 14-23
72. Kattakuzhy S, Mathur P, Gross C et al. High SVR in PWID with HCV despite imperfect medication adherence: Data from the Anchor study. *Hepatology* 2018; 68: 12A (abstract18)

73. [Anonymous]. *The National Academies of Sciences, Engineering, and Medicine. A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report*,  
<http://www.nationalacademies.org/hmd/reports/2017/national-strategy-for-the-elimination-of-hepatitis-b-and-c.aspx> (2017) Accessed: April 2020.
74. AbbVie. *Mavyret (glecaprevir/pibrentasvir) US Prescribing Information (September 2019)*,  
[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2018/209394s002lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209394s002lbl.pdf) (2019)  
Accessed: April 2020
75. Gilead. *Epclusa (sofosbuvir/velpatasvir) US Prescribing Information*,  
[https://www.gilead.com/-/media/files/pdfs/medicines/liver-disease/epclusa/epclusa\\_pi.pdf](https://www.gilead.com/-/media/files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.pdf)  
(2020) Accessed: April 2020.
76. Republic of Rwanda Ministry of Health. *Rwanda's fight in the elimination of Hepatitis C Virus*,  
[http://moh.gov.rw/index.php?id=19&tx\\_news\\_pi1%5Bnews%5D=76&tx\\_news\\_pi1%5Bday%5D=1&tx\\_news\\_pi1%5Bmonth%5D=8&tx\\_news\\_pi1%5Byear%5D=2019&cHash=5bd9a53465e639666f11d1b7aa0ea60a](http://moh.gov.rw/index.php?id=19&tx_news_pi1%5Bnews%5D=76&tx_news_pi1%5Bday%5D=1&tx_news_pi1%5Bmonth%5D=8&tx_news_pi1%5Byear%5D=2019&cHash=5bd9a53465e639666f11d1b7aa0ea60a) (2019) Accessed: April 2020.
77. Iyengar S, Tay-Teo K, Vogler S et al. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. *PLoS Med* 2016; 13: e1002032-e1002032
78. Perazzo H, Castro R, Luz PM et al. Effectiveness of generic direct-acting agents for the treatment of hepatitis C: systematic review and meta-analysis. *Bull World Health Organ* 2020; 98: 188-197K
79. VanOpdorp JR, Ferrentino N, Strader DB et al. Utility of laboratory monitoring during hepatitis C treatment with ribavirin-free direct acting antiviral regimens. *J Viral Hepat* 2019; 26: 778–781
80. D'Ambrosio R, Pasulo L, Puoti M et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. *Journal of Hepatology* 2019; 70: 379-387

81. Maasoumy B, Buggisch P, Mauss S et al. Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients. *Liver International* 2018; 38: 1906-1910
82. Cuadrado A, Llerena S, Cobo C et al. Microenvironment eradication of hepatitis C: A novel treatment paradigm. *Am J Gastroenterol* 2018; 113: 1639-1648
83. Dore G, Feld J, Thompson A et al. PS-178-Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study. *Journal of Hepatology* 2019; 70: e110
84. Mutasa-Apollo T, Ford N, Wiens M et al. Effect of frequency of clinic visits and medication pick-up on antiretroviral treatment outcomes: a systematic literature review and meta-analysis. *J Int AIDS Soc* 2017; 20: 21647
85. Welzel TM, Yang M, Sajeev G et al. Assessing patient preferences for treatment decisions for new direct acting antiviral (DAA) therapies for chronic hepatitis C virus infections. *Adv Ther* 2019; 36: 2475-2486
86. Aspinall EJ, Corson S, Doyle JS et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. *Clin Infect Dis* 2013; 57 Suppl 2: S80-89
87. Heffernan A, Cooke GS, Nayagam S et al. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. *Lancet* 2019; 393: 1319-1329
88. Loustaud-Ratti V, Debette-Gratien M, Carrier P. European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift. *World J Hepatol* 2018; 10: 639-644
89. Hepatitis C Virus Infection Consensus Statement Working Group. *Australian recommendations for the management of hepatitis C infection: a consensus statement*, <https://www.asid.net.au/documents/item/1208> (2018) Accessed: April 2020.